Document:

EX-10.14

 Exhibit 10.14 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 
 AMENDED AND RESTATED SUTROVAX AGREEMENT 

This Amended and Restated SutroVax Agreement (this “Agreement”), is made effective as of October 12, 2015 (the
“Amendment Effective Date”), by and between Sutro Biopharma, Inc., having its principal place of business at 310 Utah Ave, Suite 150, South San Francisco, CA 94080 (“Sutro”), and SutroVax, Inc., having a principal
place of business at 400 East Jamie Ct, Suite 205, South San Francisco CA 94080 (“SutroVax”), each a “Party” and collectively “Parties”, and amends and restates in its entirety that certain SutroVax
Agreement, dated August 1, 2014 (the “Effective Date”), by and between Sutro and SutroVax (the “Original Agreement”). 

WHEREAS, Sutro controls certain proprietary technology which permits cell-free expression of proteins; 

WHEREAS, SutroVax has been formed to research, develop, make and commercialize Vaccine Compositions (as defined below); 

WHEREAS, Sutro desires to continue to enable such activities, including by supplying extract and Vaccine Compositions to SutroVax, and
SutroVax desires to continue to obtain such extract and Vaccine Compositions from Sutro, on the terms and conditions set forth below; and 

WHEREAS, Sutro and SutroVax desire to amend certain terms of the Original Agreement, and to restate the Original Agreement, as so amended, in
its entirety in this Agreement, all on the terms and conditions set forth in this Agreement. 
 NOW, THEREFORE, in consideration of the
foregoing premises and the covenants and obligations set forth in this Agreement, the Parties hereby agree as follows: 
 1. DEFINITIONS. As used
herein, the following terms shall have the following meanings: 
 1.1 “Affiliate” means, with respect to either Party, any
business entity controlling, controlled by, or under common control with such Party. For the purpose of this definition only, “control” means (i) the possession, directly or indirectly, of the power to direct the management or
policies of a business entity, whether through the ownership of voting securities, by contract or otherwise, or (ii) the ownership, directly or indirectly, of at least fifty percent (50%) of the voting securities or other ownership interest of
a business entity. Notwithstanding the above, in no event shall Sutro (or any entity that would be an Affiliate of SutroVax solely because it is an Affiliate of Sutro) be deemed an Affiliate of SutroVax, or SutroVax (or any entity that would be an
Affiliate of Sutro solely because it is an Affiliate of SutroVax) an Affiliate of Sutro. 
 1.2 “Calendar Quarter” means any
three month period ending on March 31, June 30, September 30, or December 31. 
 1.3 “Change of Control”
means, with respect to a Party: (i) any Third Party becoming the beneficial owner of securities of such Party representing more than fifty percent (50%) of the total of all then outstanding voting securities; (ii) a merger or consolidation
of such Party with or into a Third Party, other than a merger or consolidation that would result in the holders of the voting securities of such Party 

 
immediately prior thereto having beneficial ownership of securities that represent immediately after such merger or consolidation more than fifty percent (50%) of the total combined voting power
of the entity that survives such merger or consolidation or the parent of the entity that survives such merger or consolidation; or (iii) the sale or disposition of all or substantially all of the assets of such Party to a Third Party wherein
the holders of such Party’s outstanding voting securities immediately before such sale do not, immediately after such sale, own or control (directly or indirectly) equity representing a majority of the outstanding voting securities of such
Third Party. 
 1.4 “Commercially Reasonable Efforts” means the level of efforts and resources (including without limitation
the promptness with which such efforts and resources would be applied) commonly used by companies in the pharmaceutical industry with respect to such activities, where the company involved is motivated to achieve the particular task or result
involved. 
 1.5 “Extract” means Sutro’s extract derived from strains of E. coli. 

1.6 “FDA” means the U.S. Food and Drug Administration, and any successor entity thereto. 

1.7 “First Commercial Sale” means, with respect to each Vaccine Composition, the first sale for which revenue has been
recognized by SutroVax or its Affiliates or Sublicensees to any Third Party for which all Regulatory Approvals (including pricing and reimbursement approvals) that are legally required in order to sell such Vaccine Composition in such country have
been granted; in each case provided, however, that the following shall not constitute a First Commercial Sale: (a) any sale to an Affiliate or Sublicensee unless the Affiliate or Sublicensee is the last entity in the distribution chain of the
Vaccine Composition, (b) any use of such Vaccine Composition in clinical trials (including post-Regulatory Approval clinical trials), non-clinical development activities or other development activities
with respect to such Vaccine Composition, or disposal or transfer of such Vaccine Composition for a bona fide charitable purpose, and (c) compassionate use. 

1.8 “Fully Burdened Manufacturing Costs” means the costs of manufacturing Extract or, if applicable, Vaccine Compositions,
which manufacturing costs shall mean: (a) [***], and (b) [***], in each case to the extent directly allocated to and incurred in the manufacture of Extracts or Vaccine Compositions (as applicable) supplied to SutroVax, its Affiliates and
Sublicensees. Fully Burdened Manufacturing Costs shall not include any [***], and shall be calculated in accordance with the foregoing, GAAP and Sutro’s policies and procedures for its other products, in each case consistently applied (and such
plant operations and support services costs shall be allocated consistent with GAAP and other products of Sutro in that facility). 
 1.9
“Net Sales” means the gross invoice amount (not including value added taxes, sales taxes, or similar taxes) of Vaccine Composition sold by SutroVax or its Affiliates or Sublicensees to the first unrelated Third Party in a bona fide
arms-length transaction after deducting, if not previously deducted, from the amount invoiced or received: 
 (a) amounts actually credited
or allowed for rejections or returns of Vaccine Composition; 
 (b) discounts, adjustments, rebates, chargebacks, retroactive price
reductions and other sales allowances that are actually allowed or granted, including rebates, reductions and allowances mandated by government; 

(c) customs or excise duties, sales tax, consumption tax, value added tax, and other governmental charges (except income taxes) in respect of
sales; 

  
 2. 

 (d) insurance, customs charges, freight, postage, shipping, handling, and other
transportation costs incurred by the applicable selling party in shipping Vaccine Composition to a Third Party; 
 (e) if Vaccine Composition
is [***], the [***]. 
 Gross invoice price of Vaccine Composition sold and the deductions allowed in subsections (a)-(e) above shall be
calculated in accordance with GAAP. 
 In the case of any sale which is not invoiced or is delivered before invoice, Net Sales shall be
calculated at the time all revenue recognition criteria are met. 
 In the case of any sale or other disposal of a Vaccine Composition
between or among SutroVax and its Affiliates or Sublicensees for resale, Net Sales shall be calculated as above only on the value charged or invoiced on the first arm’s-length sale thereafter to an
unrelated Third Party, and not on sale or disposal among SutroVax, its Affiliates and Sublicensees. Any consideration received in exchange for the transfer of Vaccine Compositions for use in clinical trials, sampling or promotional use, in each case
at or below cost, shall not be included in Net Sales. 
 In the case of any sale or other disposal for value, such as barter or
counter-trade, of any Vaccine Composition, or part thereof, other than in an arm’s-length transaction exclusively for money, Net Sales shall be calculated on any such cash consideration plus the value of
the non-cash consideration received, or the fair market price (if higher) of the Vaccine Compositions in the country of the sale or disposal. 

If a Vaccine Composition is sold as part of a Combination Product (as defined below), Net Sales will be the product of (i) Net Sales of
the Combination Product calculated as above (i.e., calculated as for a non-Combination Product) and (ii) the fraction (A/(A+B)), where: 

“A” is the gross invoice price in such country of the product comprising a Vaccine Composition as the sole active ingredient; and

 “B” is the gross invoice price in such country of the other active ingredients contained in the Combination Product. 

If “A” or “B” cannot be determined by reference to non-Combination Product sales
as described above, then Net Sales will be calculated as above, but the gross invoice price in the above equation shall be determined [***]. 

As used in this Section, “Combination Product” means a product that contains a Vaccine Composition and one or more other active
ingredients (whether coformulated or copackaged) that are not generic or other non-proprietary compositions of matter. Pharmaceutical dosage from vehicles, delivery devices, adjuvants and excipients shall be
deemed not to be “active ingredients”. 
 1.10 “Net Sublicense Fees” means any and all upfront fees, milestone
fees, and other consideration (in cash or equity) received by SutroVax or its Affiliates from a Sublicensee in consideration of the grant by SutroVax or its Affiliates of rights under Section 4.3 with respect to a Vaccine Composition, provided
that, for clarity, the following shall not be included in Net Sublicense Fees: (a) royalties or other payments based on sales included in the calculation of Net Sales (including profit sharing payments); (b) the amount of any bona fide loans;
(c) bona fide equity investments at the then-current market value; (d) support or other funding to the extent [***]; (e) reimbursement [***] for patent prosecution costs or other similar [***] expenses reasonably related to Vaccine
Compositions and incurred by SutroVax or its Affiliates pursuant to the applicable agreement with such Sublicensee [***]; 

  
 3. 

 
(f) amounts received for supply of Vaccine Compositions or other materials to such Sublicensee in accordance with this Agreement at the then-current market value; and (g) proceeds from the
sale of all or substantially all of the business or assets of SutroVax or any of its Affiliates, whether by merger, sale of stock or assets or otherwise. In the event the consideration received by SutroVax or its Affiliates from a Sublicensee
consists of equity (whether stock, interests in partnerships, joint ventures or otherwise), Sutro shall be entitled to receive a share of such equity (based on the percentages set forth in Section 6.6). In the event of a payment to SutroVax or
its Affiliate by a Sublicensee of a combined amount in consideration for both rights to a Vaccine Composition under Section 4.3 as well as other rights or value, the amount of such payment to be included in Net Sublicense Fees will be
reasonably allocated between the rights under Section 4.3 and such other rights or value (it being understood that any dispute with respect to such allocation will be resolved in accordance with Article 14). 

1.11 “Patent” means any of the following, whether existing now or in the future anywhere in the world: (i) any issued
patents, including inventor’s certificates, substitutions, extensions, confirmations, reissues, re-examinations, renewals or any like governmental grants for protection of inventions, and any extensions
or restorations of any of the foregoing, including patent term adjustments, patent term extensions and supplementary protection certificates; and (ii) any pending applications for any of the foregoing, including any continuations, divisionals,
substitutions, continuations-in-part, provisionals and utility applications and applications for extension or restoration. 

1.12 “Pneumococcal Conjugate Vaccine” means a Vaccine Composition comprising CRM197, and/or variants thereof, including but
not limited to sequences with substituted non-natural amino acids, conjugated to one or more polysaccharides as generally described in the Research Plan attached to this Agreement as of the Amendment Effective Date. 

1.13 “Regulatory Approval” means the technical, medical and scientific licenses, registrations, authorizations and approvals
(including approvals of NDAs or Biologic License Applications, supplements and amendments, pre- and post- approvals, pricing and third party reimbursement approvals, and labeling approvals) of the FDA or other
applicable regulatory authority, necessary for the development, clinical testing, commercial manufacture, distribution, marketing, promotion, offer for sale, use, import, export or sale of a pharmaceutical product in a country, including all
necessary price and/or reimbursement approvals. 
 1.14 “Research Plan” means the research plan set forth in Exhibit
A, as such plan may be amended from time to time by mutual agreement between the Parties or pursuant to Section 2.2 below. It is understood that the Research Plan as set forth in Exhibit A of the Original Agreement is hereby replaced by
Exhibit A to this Agreement. 
 1.15 “Royalty Term” means with respect to any particular Vaccine Composition in any
particular country in the Territory, the period of time beginning on the First Commercial Sale of the Vaccine Composition and extending until the later of (i) the date of expiration on a country by country basis of the last to expire of a Valid
Claim in such country of sale in which the Valid Claim covers the manufacture, use, sale, offer for sale or importation of the applicable Vaccine Composition, and (ii) ten (10) years from the First Commercial Sale of the Vaccine Composition.

 1.16 “Series A Financing” means SutroVax’s raise of a cumulative total of at least Six Million Five Hundred Thousand
U.S. dollars ($6.5 million) (whether in the form of cash raised in connection with equity financings, government or private grants, or payments from partners or collaborators, provided, however, that at least Two Million U.S. dollars ($2 million)
shall be raised in consideration for the sale of equity securities to venture capital or other institutional investors, or Strategic Investors) through one transaction or a series of transactions, excluding for such purpose the One Million

  
 4. 

 
Five Hundred Thousand U.S. Dollars ($1.5 million) received by SutroVax from Johnson & Johnson Innovation and Sutro in SutroVax’s initial convertible note financing. For such
purposes, the amounts raised shall include future payments that have not yet been received, to the extent comprised of (a) non-contingent amounts under awarded grants, (b) subsequent tranches of an
equity financing, and (c) non-contingent, non-cancellable payments from partners or other Third Parties. As used in this definition, “Strategic
Investors” means any investment entity affiliated with a nationally or internationally recognized biotechnology or pharmaceutical company or health organization or foundation (such as the Gates Foundation): (i) whose principal business is
other than the making and management of purely financial investments, (ii) who intends to make an investment in SutroVax for any reason other than potential financial gain from the appreciation of such investment (or the accrual of interest on
such investment), or (iii) who would obtain contractual rights in connection with their investment with respect to SutroVax that are other than those that would typically accompany a purely financial investment in a company. 

1.17 “Series A Financing Close” means the closing of the Series A Financing (which occurred on July 10, 2015). 

1.18 “[***] In-License” means that certain license agreement by and between SUTRO and
[***], dated [***], as may be amended from time to time. 
 1.19 “Sublicensee” means a Third Party to which SutroVax or any
of its Affiliates has granted rights under Section 4.3. 
 1.20 “Sutro Competitor” means any of the entities set forth
in Exhibit D and their respective Affiliates; provided that (i) in the event of a Change of Control of any such entity or its Affiliate, the Acquirer of such entity or its Affiliate shall not be deemed a Sutro Competitor, and
(ii) any licensee or partner of any such entity, its Affiliate or Acquirer shall not be deemed a Sutro Competitor because of such licensing or partnership arrangement. 

1.21 “Sutro Core Know-How” is defined in Section 3.3. 

1.22 “Sutro Know-How” means all information and materials pertaining to the Extracts
or Vaccine Compositions supplied hereunder, or the manufacture, use or, in the case of Vaccine Compositions, development thereof, as the case may be, that is owned or controlled by Sutro and (subject to Section 15.2) its Affiliates at any time
during the Term, including (i) practices, protocols, methods, techniques, specifications, formulae, standard operating procedures, analytical methods, material and vendor lists, (ii) analytical, quality control and stability data, batch
records, and other chemistry, manufacturing and control (CMC) data, (iii) regulatory documentation, and (iv) tangible materials and reagents; in each case as and to the extent reasonably necessary or useful for SutroVax to exercise the
rights granted to it under this Agreement. Notwithstanding the foregoing, in no event shall Sutro Know-How include any information or materials of Sutro’s third-party collaborators or sublicensees, except
for such information or materials pertaining to the Sutro Platform which Sutro has the right to provide to SutroVax in accordance with this Agreement. 

1.23 “Sutro Patent” means any Patents covering the Sutro Platform, Extracts, Vaccine Compositions, or the manufacture or use
thereof, that are owned or controlled by Sutro and (subject to Section 15.2) its Affiliates at any time during the Term. As of the Amendment Effective Date, Sutro Patents shall include those Patents listed on Exhibit B. It is understood
that the Sutro Patents as set forth in Exhibit B of the Original Agreement are hereby replaced by Exhibit B to this Agreement. 

  
 5. 

 1.24 “Sutro Platform” means Sutro’s cell-free protein synthesis
platform, including improvements thereof. 
 1.25 “SutroVax Platform Improvement Patents” means any Patents owned or
controlled by SutroVax or its Affiliates covering the SutroVax Platform Improvements at any time during the Term. 
 1.26 “SutroVax
Platform Improvements” means any and all improvements to the Sutro Platform made by or on behalf of SutroVax, its Affiliates or Sublicensees, in each case that are made using Extracts. Inventions directed to the composition, formulation or
use of Vaccine Compositions will not be considered SutroVax Platform Improvements. 
 1.27 “Term” has the meaning set forth
in Section 8.1. 
 1.28 “Territory” means worldwide. 

1.29 “Third Party” means any person other than Sutro, SutroVax and their respective Affiliates. 

1.30 “Vaccine Antigen” means any of the following antigens (each including variants thereof with biological function
substantially similar to such antigen): (i) any non-human vaccine antigen which is the same as or was derived from and directed against an infectious pathogen, including any one of a polypeptide, a
polysaccharide, a carbohydrate, or other moiety, alone or in any combination thereof, (ii) the vaccine antigens identified in the Research Plan as of the Amendment Effective Date, and (iii) the vaccine antigens, if any, selected by
SutroVax and approved by Sutro in accordance with Section 2.2. 
 1.31 “Vaccine Field” means the research, development,
manufacture, sale and other commercialization of Vaccine Compositions for prophylactic, therapeutic and/or companion diagnostic applications. 

1.32 “Vaccine Composition” means a composition comprising a Vaccine Antigen, which composition is developed and administered
for the purpose of inducing an immune response specific to such Vaccine Antigen, solely for the prevention or treatment of the disease against which such Vaccine Antigen is directed, whereby such prevention or treatment occurs through the immune
response induced by such Vaccine Antigen (excluding for clarity any form of passive immunization or use of additional molecules, including without limitation checkpoint inhibitors, to modify or otherwise affect the immune response induced by such
Vaccine Antigen provided, however, that a Vaccine Composition may include one or more adjuvants solely for use in conjunction with such Vaccine Antigen to enhance the immune response induced by such Vaccine Antigen, and, for clarity, excluding any
use with any form of passive immunization or with any checkpoint inhibitors or other additional non-adjuvant molecules), which Vaccine Composition or any portion thereof (e.g., a polysaccharide, carbohydrate,
peptide or other moiety contained in such Vaccine Composition) is discovered or produced based on the use of any Extract(s) as the starting material, whether produced by Sutro, or produced by SutroVax or a CMO established or approved by Sutro using
any Extract(s) supplied by Sutro or under a license from Sutro, in each case in any production system, whether cell-free or cell-based. Notwithstanding the foregoing, “Vaccine Composition” shall exclude any type of cancer vaccine (other
than prophylactic vaccines where the agent causing cancer is an infectious pathogen (e.g. HPV vaccine), but excluding for clarity any therapeutic cancer vaccine or companion diagnostic for cancer vaccine applications). For clarity, SutroVax’s
Pneumococcal Conjugate Vaccine is a Vaccine Composition, as defined herein. 

  
 6. 

 1.33 “Valid Claim” means a claim of (i) any issued, unexpired patent
within the Sutro Patents which has not been dedicated to the public, disclaimed, abandoned or held invalid or unenforceable by a court or other government agency of competent jurisdiction in a decision from which no appeal can be taken or is
otherwise not taken, or (ii) a pending patent application within the Sutro Patents which has not been irrevocably cancelled, withdrawn or abandoned, provided if a claim of pending patent application has not issued as a claim of an issued patent
within [***] years after the filing date from which such claim takes priority, such pending claim shall not be a Valid Claim for under this clause (ii). 

1.34 Additional Definitions. Each of the following definitions shall have the meanings defined in the corresponding sections of this
Agreement indicated below: 
  

			
	 Term
	  	 Section Defined

	Acquired Party	  	15.2(g)
	Acquirer	  	15.2(g)
	Agreement	  	Preamble
	Amendment Effective Date	  	Preamble
	Available Extract	  	3.1(d)
	Bankrupt Party	  	15.3
	Claim	  	12.1
	CMO	  	3.1(d)
	Combination Product	  	1.9
	Discloser’s Information	  	10.1
	Effective Date	  	Preamble
	Enforcement Action	  	9.2(a)(iii)
	Extract Supply Agreement	  	3.1(c)
	Initial Supply Period	  	3.1(b)
	JAMS	  	14.3
	Joint Vaccine Composition Patents	  	9.l(b)
	Lead Enforcement Party	  	9.2(a)(v)
	Marks	  	9.4
	Original Agreement	  	Preamble
	Parties	  	Preamble
	Party	  	Preamble
	Patent Term Extensions	  	9.3
	Principal Contact	  	14.1
	Prosecution and Maintenance/Prosecute and Maintain	  	9.1(d)
	Qualified Amount	  	8.5
	Restricted Vaccine Antigens	  	2.2
	Segregated Technology	  	15.2(b)
	Senior Management	  	14.2
	Strategic Investors	  	1.16
	Sublicense Agreement	  	4.3
	Sutro	  	Preamble
	Sutro Indemnitees	  	12.1
	Sutro Mark	  	9.4
	SutroVax	  	Preamble
	SutroVax Indemnitees	  	12.2
	SutroVax Marks	  	9.4
	Vaccine Antigen Notice	  	2.2
	Vaccine Field Infringement	  	9.2(a)(i)
	Vaccine Composition-Specific Patents	  	9.1(a)(i)
	Vaccine Composition Supply Agreement	  	3.2(b)

  
 7. 

 2. RESEARCH PLAN 

2.1 Sutro Obligations. Prior to Series A Financing Close, Sutro will: 

(a) evaluate the expression of up to [***] Vaccine Antigens identified in the Research Plan as of the Effective Date through the Sutro Platform
as described in the Research Plan; 
 (b) use Commercially Reasonable Efforts to deliver to SutroVax for testing [***] of each Vaccine
Antigen, for up to [***] Vaccine Antigens identified in the Research Plan as of the Effective Date; 
 (c) perform assays and/or analytical
work for up to [***] Vaccine Antigens identified in the Research Plan as of the Effective Date, as may be mutually agreed between the Parties in writing. 

2.2 Designation of Additional Vaccine Antigens. SutroVax may select up to [***] additional (i.e., in addition to the vaccine antigens
identified in the Research Plan as of the Amendment Effective Date) vaccine antigens that are not for the prevention or treatment of any infectious disease or cancer, solely for development as Vaccine Compositions under the terms of this Agreement,
by providing written notice to Sutro, within [***] years from the Series A Financing Close, of each such additional Vaccine Antigen proposed by SutroVax (each a “Vaccine Antigen Notice”), which Vaccine Antigen Notice shall include
(i) the common name of such Vaccine Antigen, (ii) the specific amino acid sequence thereof, and (iii) such other information as Sutro reasonably requests. Sutro shall notify SutroVax within [***] of receipt of the Vaccine Antigen
Notice as to whether it accepts or not such additional Vaccine Antigen proposed by SutroVax, provided that Sutro shall not withhold its acceptance of a proposed Vaccine Antigen (other than a Restricted Vaccine Antigen) that is available , it being
understood that, with respect to [***], Sutro [***]. For such purposes, a proposed Vaccine Antigen shall be “available,” unless Sutro (a) [***] , (b) is [***] or (c) has [***]. Upon Sutro’s acceptance of a proposed Vaccine
Antigen, such Vaccine Antigen shall be deemed a Vaccine Composition, in which case the Research Plan shall be amended to include any mutually agreed upon activities to be performed by Sutro with respect to such Vaccine Antigen. For purposes of this
Section 2.2, “Restricted Vaccine Antigens” means vaccine antigens for the treatment of autoimmune or inflammatory diseases where inflammation is characterized by specific immune responses directed to self antigens. 

3. SUPPLY 
 3.1 Extract Supply. 

(a) Prior to the Series A Financing Close, Sutro shall use Commercially Reasonable Efforts to manufacture and supply, at no cost to SutroVax,
the Extracts specified in the Research Plan. 
 (b) For [***] years following the Series A Financing Close (“Initial Supply
Period”), Sutro shall use Commercially Reasonable Efforts to manufacture and supply the quantities of Extract(s) set forth in a mutually agreed upon research plan, based on the Series A work plan, at a price equal to Fully Burdened
Manufacturing Costs plus [***]. Sutro agrees not to unreasonably withhold its agreement to such a research plan. 

  
 8. 

 (c) Following SutroVax’s achievement of the diligence milestone 2(a) set forth in
Exhibit C, if requested by SutroVax, on an Extract-by-Extract basis, the Parties shall negotiate in good faith reasonable terms and conditions of an agreement for
the supply by Sutro to SutroVax of the quantities of the Extract reasonably requested by SutroVax to manufacture the applicable Vaccine Composition(s) (but excluding, for clarity, any provision granting to SutroVax or its Affiliates or Sublicensees
any right to obtain or use any Sutro Core Know-How), which terms shall be negotiated in good faith by the Parties, provided that the price for each Extract shall not exceed [***] of the Fully Burdened
Manufacturing Cost thereof (each such agreement, an “Extract Supply Agreement”). 
 (d) In the event Sutro engages one or
more Third Parties or establishes a joint venture with one or more Third Parties (each such Third Party or joint venture, a “CMO”), to manufacture one or more Extract(s) for Sutro, its Affiliates or others (each such Extract, an
“Available Extract”), Sutro shall promptly notify SutroVax. 
 (i) In the event one or more of the Extracts used by SutroVax
to manufacture Vaccine Compositions under this Agreement are Available Extracts, and SutroVax wishes the CMO to supply such Available Extract(s) to SutroVax, SutroVax shall notify Sutro thereof. At SutroVax’s request, Sutro agrees to authorize
such CMO to supply to SutroVax SutroVax’s reasonable requirements of such Available Extract(s) solely to manufacture Vaccine Compositions in accordance with this Agreement, under an agreement to be entered into by SutroVax and CMO, it being
understood that Sutro shall not be liable to SutroVax or such CMO for any breach of such agreement by such CMO or SutroVax, respectively. SutroVax shall at Sutro’s request provide to Sutro a copy of such agreement. 

(ii) In the event one or more Extract(s) used by SutroVax to manufacture Vaccine Compositions under this Agreement are not Available Extracts,
and SutroVax wishes the CMO to supply any such Extract(s) to SutroVax, SutroVax shall notify Sutro thereof. At SutroVax’s request, Sutro agrees to authorize such CMO to supply to SutroVax SutroVax’s reasonable requirements of such
Extract(s) solely to manufacture Vaccine Compositions in accordance with this Agreement, under an agreement to be entered into by SutroVax and CMO, it being understood that Sutro shall not be liable to SutroVax or such CMO for any breach of such
agreement by such CMO or SutroVax, respectively. SutroVax shall provide to Sutro a copy of such agreement promptly following its execution. Upon receipt of such copy, Sutro shall (a) transfer to such CMO as soon as reasonably practicable the
items of Sutro Know-How reasonably necessary for such CMO to manufacture the specific Extract(s) identified in such agreement, and (b) make its personnel that is knowledgeable regarding the Sutro Platform
(“Sutro Personnel”) reasonably available to such CMO for scientific and technical explanations and on-site support that may reasonably be requested by such CMO to perform the activities set
forth in this Section 3.1(d)(ii), provided however, that SutroVax shall [***]. 
 (e) If Sutro undergoes a Change of Control and there
is not in place at least one CMO who has supplied Extract to Sutro or a Third Party and who has adequate capabilities to manufacture and supply SutroVax’s reasonable requirements of Extract(s) to manufacture Vaccine Compositions under this
Agreement, and is willing to supply such requirements under reasonable and customary terms consistent with this Agreement (but excluding, for clarity, any provision granting to SutroVax or its Affiliates or Sublicensees any right to obtain or use
any Sutro Core Know-How), then at SutroVax’s request, Sutro, shall as soon as reasonably practicable, identify a CMO reasonably acceptable to SutroVax (the approval of such CMO not to be unreasonably
withheld, conditioned or delayed by SutroVax). At SutroVax’s request, Sutro agrees to (a) authorize such CMO to supply to SutroVax SutroVax’s reasonable requirements of such Extract(s) and (b) use good faith efforts to assist
SutroVax in connection with the negotiation by SutroVax of an agreement between SutroVax and such CMO for the supply by such CMO to SutroVax of SutroVax’s reasonable requirements of Extracts, under reasonable and customary terms and conditions
consistent with this Agreement (but excluding, for clarity, any provision granting to 

  
 9. 

 
SutroVax or its Affiliates or Sublicensees any right to obtain or use any Sutro Core Know-How), it being understood that Sutro shall not be liable to
SutroVax or such CMO for any breach of such agreement by such CMO or SutroVax, respectively. SutroVax shall provide to Sutro a copy of such agreement promptly following its execution. Upon receipt of such copy, Sutro shall (i) transfer to such
CMO as soon as reasonably practicable the items of Sutro Know-How reasonably necessary for such CMO to manufacture the specific Extract(s) identified in such agreement, and (ii) make Sutro Personnel
reasonably available to such CMO for scientific and technical explanations and on-site support that may reasonably be requested by such CMO to perform the activities set forth in this Section 3.1(e),
provided however, that SutroVax shall [***]. It is understood the CMO selected by Sutro under this Section 3.1 shall be a reputable and established manufacturer [***]. Furthermore, from and after Sutro’s Change of Control, in the event
Sutro’s existing CMO engaged or established under Section 3.1 discontinues the supply of Extracts to SutroVax and is unable to resume such supply in a reasonable timeframe (whether due to bankruptcy, Change of Control or otherwise), at
SutroVax’s request, Sutro shall, as soon as reasonable practicable, establish another CMO in accordance with the terms and conditions set forth in this Section 3.1(e) (including for clarity SutroVax’s payment obligation set forth
above). 
 3.2 Vaccine Composition Supply. 

(a) Prior to the Series A Financing Close, Sutro will use Commercially Reasonable Efforts to manufacture and supply, at no cost to SutroVax,
the non-cGMP Vaccine Compositions specified in the Research Plan. 
 (b) Following the Series A
Financing Close, in the event that SutroVax desires Sutro to manufacture and supply cGMP Vaccine Compositions, then SutroVax shall inform Sutro in writing thereof, and if requested by SutroVax, on a Vaccine Composition-by-Vaccine Composition basis, Sutro shall supply to SutroVax the quantities of Vaccine Composition(s) reasonably requested by SutroVax, in each case under a supply agreement for such Vaccine
Composition(s) (each, a “Vaccine Composition Supply Agreement”), that shall contain such terms and conditions as are reasonable and customary for arrangements of this type (but excluding, for clarity, any provision granting to
SutroVax or its Affiliates or Sublicensees any right to obtain or use any Sutro Core Know-How), which terms shall be negotiated in good faith by the Parties, provided that the price for each Vaccine
Composition shall not exceed [***] of the Fully Burdened Manufacturing Cost thereof. 
 (c) If Sutro engages one or more CMO(s) to
manufacture and supply cGMP proteins using the Sutro Platform, Sutro will promptly notify SutroVax. In the event SutroVax wishes the CMO to supply cGMP Vaccine Compositions to SutroVax, SutroVax shall notify Sutro thereof. At SutroVax’s
request, Sutro agrees to authorize (and cooperate in good faith to facilitate) such CMO to supply to SutroVax SutroVax’s reasonable requirements of such cGMP Vaccine Compositions under an agreement to be entered into by SutroVax and CMO, it
being understood that Sutro shall not be liable to SutroVax or such CMO for any breach of such agreement by such CMO or SutroVax, respectively. SutroVax shall at Sutro’s request provide to Sutro a copy of such agreement. Following the execution
of such agreement, Sutro shall (i) upon SutroVax’s written request, transfer to such CMO any item of Sutro Know-How related to Vaccine Compositions (excluding for clarity any Sutro Core Know-How) reasonably necessary for such CMO to manufacture the specific cGMP Vaccine Compositions identified in such agreement for the sole purpose of such CMO manufacturing Vaccine Compositions under the agreement
with SutroVax, and (ii) make Sutro Personnel reasonably available to such CMO for scientific and technical explanations and on-site support that may reasonably be requested by such CMO to perform the
activities set forth in this Section 3.2(c), provided however, that [***]. 

  
 10. 

 (d) Subject to the terms of the Agreement, following the Series A Financing Close, SutroVax
shall be allowed to select and engage a CMO, subject to Sutro’s approval not to be unreasonably withheld, conditioned or delayed by Sutro, to supply to SutroVax SutroVax’s reasonable requirements of cGMP Vaccine Compositions under an
agreement to be entered into by SutroVax and CMO, it being understood that Sutro shall not be liable to SutroVax or such CMO for any breach of such agreement by such CMO or SutroVax, respectively. To the extent that, following the execution of such
agreement, any item of Sutro Know-How related to Vaccine Compositions (excluding for clarity any Sutro Core Know-How) is reasonably necessary for such CMO to manufacture
for SutroVax the specific cGMP Vaccine Compositions identified in the agreement, then Sutro shall transfer such Sutro Know-How to SutroVax and SutroVax shall be responsible for providing such Sutro Know-How to such CMO for the sole purpose of such CMO manufacturing Vaccine Compositions under the agreement with SutroVax, provided however, that SutroVax shall [***]. For clarity, in the event the CMO engaged or
established under Section 3.2(d) discontinues the supply of Vaccine Compositions to SutroVax and is unable to resume such supply in a reasonable timeframe (whether due to bankruptcy, Change of Control or otherwise), at SutroVax’s request,
Sutro shall, as soon as reasonable practicable, assist SutroVax in establishing another CMO in accordance with the terms and conditions set forth in this Section 3.2(d) (including for clarity SutroVax’s payment obligation set forth above).

 (e) Notwithstanding Section 4.2, once a CMO (selected and/or approved by Sutro, as applicable) is established in accordance with this
Section 3.2, SutroVax shall have the right to supply to such CMO Extracts obtained by SutroVax in accordance with Section 3.1, in each case solely for use for the purpose of such CMO manufacturing and supplying Vaccine Compositions to
SutroVax, its Affiliates and Sublicensees in accordance with this Agreement. 
 (f) For clarity, and notwithstanding the foregoing, it is
understood that Sutro shall be obligated to supply only those Vaccine Compositions, or components of such Vaccine Compositions (such as an adjuvant), that are produced using Extract, and the provisions of this Article 3 shall apply with respect to
such components in the same manner as they apply to Vaccine Compositions (mutatis mutandis). 
 3.3 Additional CMO Terms. For clarity,
except as set forth in Section 15.3, in no event shall SutroVax, its Affiliates or Sublicensees have the right to access to any processes, documents, and materials or other Know-How owned or controlled by
Sutro that relate to the manufacture or supply of Extracts (including, but not limited to, Know-How regarding the generation and/or use of strains from which Extract is produced) (collectively, “Sutro
Core Know-How”), whether directly from Sutro or its Affiliates or through a CMO or otherwise, and SutroVax, its Affiliates and Sublicensees shall not require, request or solicit any CMO to deliver any
Sutro Core Know-How to SutroVax, its Affiliates and/or its Sublicensees, and no agreement between any CMO and Sutro, its Affiliates and Subsidiaries shall contain any provision granting to SutroVax or its
Affiliates or Sublicensees any right to obtain or use any Sutro Core Know-How. Without limiting the foregoing, in the event any item of Sutro Core Know-How is delivered to SutroVax, its Affiliates and/or its
Sublicensees (except as set forth in Section 15.3), SutroVax, its Affiliates and Sublicensees shall immediately return such item to Sutro. Notwithstanding the foregoing, to the extent SutroVax or its Sublicensee is required by a regulatory
authority (or applicable law) in the United States, Europe or Japan to confidentially disclose, as part of the applicable regulatory filings with respect to a Vaccine Composition, any Sutro Core Know-How (for
clarity, excluding any tangible embodiments of such Sutro Core Know-How other than information and documentation), Sutro shall, upon SutroVax’s written request, confidentially disclose such Sutro Core Know-How as part of the applicable regulatory filings, subject to the payment obligations set forth in Section 5.4 of this Agreement. 

  
 11. 

 3.4 No Additional Royalties. The Parties acknowledge and agree that the only payments
to be made by SutroVax to Sutro, directly or indirectly, in consideration for the rights licensed under Section 4.1(a), with respect to Vaccine Compositions will be the royalties and Net Sublicense Fees specified in Article 6 of this Agreement.
Accordingly, Sutro shall not charge additional royalties or other similar payments in consideration for such rights from any CMO engaged or approved by Sutro pursuant to Section 3.1 or 3.2 with respect to the supply of Extracts or Vaccine
Compositions (as applicable) which would flow through to SutroVax on Extracts or Vaccine Compositions supplied by such CMO to SutroVax, its Affiliates or Sublicensees (as applicable). For clarity, this Section 3.4 shall not be construed to
prevent or restrict Sutro from charging the applicable CMO and/or SutroVax a reasonable transfer price (with respect to supply to SutroVax, subject to the applicable price set forth in Section 3.1) for the supply of Extract following the Series
A Financing Close. 
 4. SUTROVAX RIGHTS 

4.1 License Grant. 
 (a)
Subject to the terms of this Agreement, Sutro hereby grants to SutroVax an exclusive, royalty-bearing license, under Sutro Patents and Sutro Know-How, with the right to grant and authorize sublicenses in
accordance with Section 4.3 (only with respect to the rights granted under the following sub-clause (i)), solely to (i) research, develop , use, sell, offer for sale, export, import or otherwise
exploit Vaccine Compositions, and (ii) to manufacture, itself or through any CMO established or approved by Sutro pursuant to Section 3.2, both cGMP grade and non-cGMP grade Vaccine Compositions from
Extracts obtained from Sutro or any CMO established or approved by Sutro as described in Section 3.1, in each case in the Territory during the Term in accordance with the terms of the Agreement. For clarity, to the extent a CMO established in
accordance with Section 3.2 above utilizes Sutro Patents or Sutro Know-how solely to supply Vaccine Composition to SutroVax in accordance with Section 3.2, such arrangement shall not be deemed a
sublicense by SutroVax. In addition, it is understood and agreed that: 
 (A) If components of a Vaccine Composition (such as
an adjuvant) can be used for purposes other than a Vaccine Composition, the exclusive license under this Section 4.1 shall not be deemed to restrict Sutro from using, licensing or otherwise exploiting such components for such other purposes
(i.e., purposes other than to induce an immune response specific to a Vaccine Antigen to treat or prevent the disease against which such Vaccine Antigen is directed by means of such specific immune response); and 

(B) If a Vaccine Composition or component thereof can be used for purposes other than those permitted under Section 1.32,
such use shall not be deemed licensed under this Section 4.1, but a third party’s use or administration of a composition for such an unpermitted use shall not cause such composition to cease being a Vaccine Composition, provided that
SutroVax uses diligent efforts to prevent such unpermitted use. 
 (b) For clarity, SutroVax [***], and shall use the Extracts supplied to it
by Sutro or a CMO authorized by Sutro solely to express Vaccine Compositions in the Territory solely for use in conjunction with the exercise, and within the scope, of the license granted in Section 4.1(a). 

(c) Subject to the terms of the Agreement and except as otherwise set forth hereunder, Sutro shall not, during the Term, provide Extract or
Vaccine Compositions to any Third Party for uses that would be within the scope of the license granted in Section 4.1(a) or use or otherwise exploit Extract or Vaccine Compositions for uses that would be within the scope of the license granted
in Section 4.1(a), provided that, for clarity, (A) Sutro retains the right (i) to produce Extracts, to supply Extracts to SutroVax and Third Parties, and to authorize CMOs to produce Extracts, in each case for purposes of
manufacturing Vaccine Compositions for SutroVax and its designees; and (ii) to perform Sutro’s obligations under Article 3, and (B) as between the Parties, Sutro retains all rights to produce, use and exploit Extracts outside the
Vaccine Field. 

  
 12. 

 (d) Notwithstanding the foregoing, in the event any Sutro
Know-How or Sutro Patents are first in-licensed or first acquired following the Effective Date from a Third Party on a royalty-,
fee- or other similar basis, then, to the extent Sutro has the right to grant a license to such Sutro Know-How or Sutro patents under Section 4.1(a), the inclusion
of such Sutro Know-How and Sutro Patents in such license shall be conditioned upon the Parties’ mutual written agreement for SutroVax to reimburse Sutro for any amount payable by Sutro to such Third Party as a result of SutroVax’s exercise
of its license to such Sutro Know-How and Sutro Patents under this Agreement. 
 (e) Notwithstanding
anything to the contrary, this Agreement, including the licenses granted under this Section 4.1 shall be subject to, and limited by, the terms of the [***] In-License, and SutroVax agrees to comply with the terms set forth in Exhibit E.

 4.2 No Other Uses. SutroVax covenants not to use the Extract except for use in conjunction with the exercise, and within the scope,
of the license granted in Section 4.1(a). Without limiting the foregoing, SutroVax shall not (a) [***], sell, transfer, lease, exchange or otherwise dispose of or provide Extract to any Third Party, (b) engineer or reverse-engineer any E.
coli strain for the purpose of producing extract in connection with cell-free protein synthesis, (c) knowingly use Extract to produce cancer vaccines or any other proteins except for Vaccine Compositions, and (d) use Extract in human
subjects, in clinical trials, or for diagnostic purposes involving human subjects. In addition, SutroVax will store and use the Extract and Vaccine Compositions supplied to it hereunder in compliance with all applicable laws, regulations, and
guidelines, including without limitation those governing handling and disposal of hazardous materials. In the event of breach of this Section 4.2 by SutroVax, its Affiliates or Sublicensees, notwithstanding Section 8.2, Sutro may
immediately terminate this Agreement upon notice to SutroVax. 
 4.3 Further Development. Subject to the terms of this Agreement,
SutroVax may grant and authorize sublicenses to Affiliates and Third Parties under the licenses granted to it under Section 4.1(a)(i), to further develop, offer to sell, import, export and otherwise exploit Vaccine Compositions discovered or
generated at least in part by SutroVax or its Affiliate under the terms of this Agreement (or derivatives thereof with a substantially similar biological function), provided that (a) in no event shall any such Affiliate or Third Party be
granted the right to independently develop additional Vaccine Compositions that were not discovered or developed at least in part by SutroVax or its Affiliate (or that are not derivatives thereof with a substantially similar biological function),
and (b) each such Affiliate or Third Party shall enter into a written agreement (each, a “Sublicense Agreement”) the terms of which are consistent with the terms of this Agreement. For clarity, in no event shall SutroVax grant
or authorize sublicenses to Third Parties to use the Extracts to independently discover or generate Vaccine Compositions. SutroVax shall remain responsible for its obligations under this Agreement, and shall ensure that each such agreement contains
terms and conditions requiring the applicable Affiliate or Third Party to comply with the terms and conditions under Sections 12.1(a) (and the corresponding provisions of Section 12.3) and 12.4, in each case to the extent applicable to
activities of the Sublicensee. SutroVax shall deliver to Sutro a true, correct, and complete copy of any Sublicense Agreement no later than [***] days after the execution of such agreement, provided that any Sublicense Agreement shall be deemed
Discloser’s Information of SutroVax under Article 10 below. 
 4.4 Technology Transfer. Upon request by SutroVax, Sutro shall
provide SutroVax with (i) copies of, or access to, the then-existing Sutro Know-How that is reasonably necessary to enable SutroVax to exercise the rights granted to it in Section 4.1(a) and listed
in Exhibit F (excluding for clarity any Sutro Core Know-How), (ii) reasonable on-site training at Sutro’s premises to enable SutroVax to implement such Sutro
Know-How, and (iii) reasonable access, during ordinary business hours, to Sutro’s personnel knowledgeable of the Sutro Platform for technical advice with respect to the implementation of such Sutro Know-How, whether by teleconference or in-person meeting. After the initial transfer under (i) above, upon request no more than [***], Sutro shall provide to SutroVax
copies of, or access to, any 

  
 13. 

 
Sutro Know-How developed or acquired following the initial transfer and falling in the categories set forth in Exhibit F, in each case as reasonably
necessary to enable SutroVax to exercise the rights granted to it in Section 4.1(a) and was not previously provided to SutroVax under this Section 4.4 (excluding for clarity any Sutro Core Know-How).
Sutro shall perform the activities set forth in this Section 4.4 at no cost to SutroVax, provided, however, that following the Series A Financing Close, the performance of the activities set forth in the foregoing
sub-clauses (ii) and (iii) shall be subject to the payment to Sutro of all documented time spent by Sutro’s personnel to perform such transfer (on an FTE basis) and out-of-pocket costs incurred by Sutro in connection with performing such activities, in accordance with a budget reasonably approved in advance by SutroVax. 

4.5 Grant-Back. Subject to the terms and conditions of this Agreement, SutroVax hereby grants to Sutro and its Affiliates, and shall
cause its Sublicensees to grant to Sutro and its Affiliates, an exclusive (including as to SutroVax, its Affiliates and Sublicensees), perpetual, royalty-free, worldwide license, with the right to sublicense through multiple tiers, to exploit any
SutroVax Platform Improvements in any field other than the Vaccine Field (except as may be necessary for Sutro to fulfill its obligations under this Agreement or any manufacturing or supply agreement entered into hereunder). 

5. REGULATORY ACTIVITIES 
 5.1 As between
the Parties, SutroVax shall be solely responsible for preparing and filing of any and all regulatory submissions for Vaccine Compositions in the Territory and shall own all related regulatory materials, provided, however , that Sutro shall have the
authority to approve, and have final responsibility for, the CMC portions of such submissions and materials to the extent relating to the manufacturing of Extracts. 

5.2 SutroVax shall keep Sutro informed of pre-clinical, clinical and regulatory developments relating
to Vaccine Compositions in the Territory through regular reports to Sutro as set forth in Section 7.3, and SutroVax shall promptly notify Sutro of any Regulatory Approval received for each Vaccine Composition in the Territory. SutroVax shall
provide Sutro for review and comment the relevant CMC portions and portions concerning product safety of draft material regulatory filings with respect to Vaccine Compositions at least [***] days in advance of their intended date of submission to a
regulatory authority in the Territory and shall consider in good faith any comments thereto provided by Sutro. SutroVax shall promptly notify Sutro with copies of any such CMC portions and portions concerning product safety of material regulatory
submissions or communications submitted to or received from any regulatory authority in the Territory and shall provide Sutro with copies thereof within [***] days after submission or receipt. SutroVax shall provide Sutro with reasonable advance
notice of all meetings, conferences, and discussions scheduled with any regulatory authority in the Territory in each case to the extent concerning relevant CMC information, adverse events or other safety information with respect to a Vaccine
Composition, and shall consider in good faith any input from Sutro in preparing for such meetings, conferences or discussion. To the extent permitted by applicable laws, Sutro shall have the right to participate, in any such meetings, conferences or
discussions to the extent the same concern CMC information, CMC activities, adverse events or other safety information with respect to any Vaccine Composition. For clarity, and notwithstanding any of the foregoing, SutroVax’s obligations under
this Section 5.2, including with respect to any regulatory developments, Regulatory Approvals, regulatory filings, submissions, communications, meetings, conferences, and discussions, and safety information , shall in each case (i) apply
only to the extent they are directed to CMC information or CMC activities, adverse events or other safety information that are pertinent to use of the Sutro Platform within the Vaccine Field and (ii) to the extent that SutroVax has the right to
comply under its agreements with Third Parties; provided that in any case SutroVax shall use Commercially Reasonable Efforts to keep Sutro reasonably informed regarding progress of the Vaccine Compositions. 

  
 14. 

 5.3 SutroVax shall (i) promptly provide Sutro any and all relevant CMC data and
evaluations, adverse event reports and other safety information controlled by SutroVax that are generated from development and testing (including without limitation human clinical trials) performed or sponsored by any of SutroVax, its Affiliates, or
Sublicensees with respect to any Vaccine Composition, all to the extent the same contain CMC information, adverse event or other safety information pertinent to use of the Sutro Platform outside the Vaccine Field, and (ii) grant Sutro, its
Affiliates and Third Party licensees to whom Sutro has granted rights to the Sutro Platform, the right to reference any regulatory filings and Regulatory Approvals controlled by SutroVax that are filed by SutroVax, its Affiliates or Sublicensees
with respect to any Vaccine Compositions, to the extent reasonably necessary or useful for obtaining Regulatory Approvals for products produced using the Sutro Platform outside the Vaccine Field (in each case of (i) and (ii), to the extent
SutroVax has the right to grant such rights to Sutro). Similarly, upon SutroVax’s request, Sutro agrees to grant SutroVax, its Affiliates and Sublicensees the right to reference any regulatory filings and Regulatory Approvals controlled by
Sutro that are filed by Sutro, its Affiliates or Third Party licensees with respect to any products produced using the Sutro Platform, to the extent reasonably necessary or useful for obtaining Regulatory Approvals for Vaccine Compositions (in each
case, to the extent Sutro has the right to grant such rights to SutroVax). 
 5.4 As requested by SutroVax from time to time, Sutro shall
reasonably cooperate with and provide assistance to SutroVax in connection with the preparation, submission and maintenance of regulatory applications and other filings to regulatory authorities regarding any Vaccine Composition, to the extent they
require information controlled by Sutro or its contractors, provided, however, that following the Series A Financing Close, the performance of the foregoing activities shall be subject to the payment to Sutro of all documented time spent by
Sutro’s personnel to perform such assistance and/or out-of-pocket costs for performing such activities. Accordingly, Sutro shall promptly provide SutroVax upon
SutroVax’s written request with all available information controlled by Sutro or its Affiliates as reasonably necessary for SutroVax to apply for, obtain, and maintain such regulatory applications and filings in any country regarding any
Vaccine Composition. To the extent that Sutro may reasonably satisfy such requirements by submitting and maintaining one or more Drug Master Files or other similar regulatory filings with the FDA and other regulatory authorities for the Extracts or
Vaccine Compositions, Sutro may satisfy its obligation under this Section 5.4 by doing so and providing SutroVax, its Affiliates and Sublicensees appropriate rights to reference such Drug Master Files or such other confidential regulatory
materials, and Sutro further agrees to make such filings and provide such rights of reference if requested by SutroVax (it being understood that SutroVax, its Affiliates and Sublicensees shall not have access to the information contained of such
Drug Master Files or other confidential regulatory materials). Further, Sutro agrees, at SutroVax’s request and expense, to execute, acknowledge and deliver such further instruments, and take such other actions, all as promptly as possible,
which may reasonably be necessary or appropriate to assist in the filing for, preparation, submission and maintenance of such regulatory applications, filings and communications, to the extent Sutro has the right to do so. Without limiting the
foregoing, Sutro shall keep SutroVax reasonably informed on regulatory matters affecting or implicating the Sutro Platform generally to the extent such matters would be reasonably expected to have a material impact on Vaccine Compositions. For
clarity, and notwithstanding any of the foregoing, Sutro’s obligations under this Section 5.4, shall (i) apply only to the extent the regulatory information is directed to CMC information or CMC activities, adverse events or other
safety information that are pertinent to use of the Sutro Platform within the Vaccine Field or (subject to the last sentence of Section 5.4) is otherwise reasonably necessary for the preparation, submission and maintenance of regulatory
applications and other filings to regulatory authorities in the United States, Europe or Japan regarding any Vaccine Composition, and (ii) to the extent that Sutro has the right to comply under its agreements with Third Parties. 

  
 15. 

 5.5 Sutro shall permit applicable regulatory authorities to conduct inspections of its
manufacturing facilities, inspect and make copies of any relevant records (or copies thereof, as applicable) as they may request and shall cooperate with such regulatory agencies with respect to the inspections and any related matters, in each case
which is related to any Vaccine Composition or the manufacture thereof. Sutro shall give SutroVax prior notice, to the extent practicable, of any inspections of its facilities relevant to use of the Sutro Platform for Vaccine Compositions, and keep
SutroVax informed about the results and conclusions of each such regulatory inspection, including actions taken to remedy conditions cited in the inspections. Sutro will promptly provide SutroVax with copies of any written inspection reports issued
by the applicable regulatory authority and all correspondence between Sutro and regulatory authorities, in each case to the extent the same relate to the production of Extract for Vaccine Compositions or production of Vaccine Compositions supplied
hereunder and similarly, Sutro agrees to promptly notify and provide SutroVax copies of any request, directive or other communication of regulatory authority relating to Extracts related to Vaccine Compositions or Vaccine Compositions supplied
hereunder, and to cooperate with SutroVax in responding to such requests, directives and communications, it being understood that any materials provided to SutroVax under this Section 5.5 shall be deemed Discloser’s Information of Sutro
under Section 10.1; each as further described in the applicable Extract Supply Agreement or Vaccine Composition Supply Agreement, as applicable. 

5.6 Sutro further agrees to reasonably cooperate with SutroVax to allow SutroVax’s potential Sublicensees or partners to conduct
reasonable due diligence with respect to the supply of Extracts or Vaccine Compositions prior to execution of a Sublicense agreement (but excluding for clarity any audit of Sutro’s processes, documentation and personnel). The applicable Extract
Supply Agreement or Vaccine Composition Supply Agreement for the particular Vaccine Composition(s) licensed to such Sublicensee will include reasonable and customary provisions for Sublicensees, after execution of a Sublicense agreement, to perform
quality assurance reviews relevant to the production of Vaccine Compositions; provided that such provisions will limit the Sublicensee’s access to confidential information of Sutro pertaining to methods, parameters, processes and the like used
to produce Extract. Sutro shall use Commercially Reasonable Efforts to obtain from its contractors commitments similar to those contemplated in this Section 5.6. 

6. FINANCIAL TERMS 
 6.1 SutroVax shall pay
to Sutro the following royalties during the applicable Royalty Term: 
 (a) four percent (4%) of aggregate Net Sales of Vaccine Compositions
for human health use; 
 (b) two percent (2%) of aggregate Net Sales of Vaccine Compositions for animal health use. 

6.2 Royalties shall be due under Section 6.1, on a Vaccine
Composition-by-Vaccine Composition basis, until the end of the Royalty Term for such Vaccine Composition, provided that the amounts set forth in Section 6.1 shall
be reduced, on a country-by-country and Vaccine Composition by-Vaccine Composition basis, by [***], during any portion of the
Royalty Term in which (a) there is not at least one Valid Claim of Sutro Patents covering the manufacture, use, sale, offer for sale or importation of the applicable Vaccine Composition in the country of sale, and (b) extract for cell-free
protein synthesis that has been qualified for production of proteins by the applicable regulatory authority is commercially available from at least one supplier other than Sutro, its Affiliates or Third Parties licensed or engaged by Sutro. 

6.3 In the event that a Vaccine Composition is being sold by a Sublicensee and SutroVax is receiving royalties from such Sublicensee on Net
Sales by such Sublicensee at a royalty rate that is [***], to the extent the Sublicensee has the right to reduce its royalty payment to SutroVax with respect to such Net Sales in connection with the launch of one or more biosimilar, biocomparable,
biogeneric, bioequivalent or the like with respect to any Vaccine Composition under the applicable Sublicense 

  
 16. 

 
Agreement, SutroVax’s royalty obligation to Sutro with respect to Net Sales of the applicable Vaccine Composition by such Sublicensee shall be [***] (by way of example, if a Sublicensee has
the right to reduce royalty payment to SutroVax by [***], SutroVax shall have the right to reduce royalty payment to Sutro based on Net Sales of the applicable Vaccine Composition by such Sublicensee by [***]), provided that in no event shall the
applicable royalty rate for Net Sales of such Vaccine Composition be reduced pursuant to this Section 6.3 by more than [***] from the applicable rate set forth in Section 6.1 above. 

6.4 If SutroVax, its Affiliate or Sublicensee determines to license any Patent or other intellectual property rights owned by a Third Party in
order to make, use, or sell any product incorporating Vaccine Composition, SutroVax will have the right, upon obtaining such a license from such Third Party, to credit [***] of any [***] made to such Third Party with respect to such product against
up to [***] of the royalties otherwise payable to Sutro with respect to the same product under Section 6.1. 
 6.5 Notwithstanding
anything to the contrary, to the extent that Sutro owes royalties under the [***] In-License on sales of Vaccine Compositions by SutroVax, its Affiliates and/or Sublicensees greater than the royalties that
would be payable to Sutro under Sections 6.1-6.4 (or owes royalties on sales for which no royalties would be payable to Sutro under Sections 6.1-6.4), then SutroVax
shall pay to Sutro any such royalties due under the [***] In-License upon Sutro’s written request, provided that the amount of royalties payable under this Section 6.5 shall not exceed the amount of
royalties Sutro would owe to [***] under the [***] In-License on sales of Vaccine Compositions by SutroVax as of the Effective Date. 
 6.6
In addition to the royalties payable under Section 6.1, subject to Section 15.2(e) below, SutroVax shall pay to Sutro a percentage of any and all Net Sublicense Fees obtained by SutroVax, as described in the following table: 

 

			
	 Timing of Sublicense Agreement Execution
	  	Percentage of Net Sublicense Fees
	 [***]
	  	[***]
	 [***]
	  	[***]

 If SutroVax, its Affiliate or Sublicensee grants a Third Party an option or contingent right to enter into a
Sublicense Agreement, and the exercise of such right or option results in such Sublicense Agreement, the time when such initial grant of such option or other contingent right was made shall be deemed to be the time when such agreement was entered
for purposes of this Section 6.5. For the avoidance of doubt, SutroVax shall not be obligated to pay to Sutro any Net Sublicense Fees received under a Sublicense Agreement executed [***]. 

6.7 All amounts payable pursuant to Sections 6.1 and 6.6 of this Agreement shall be due quarterly (i) within [***] days following the end
of each Calendar Quarter in respect of Net Sales by SutroVax or its Affiliate, or within [***] days following SutroVax’s receipt of royalty payments from its Sublicensee with respect to Net Sales by such Sublicensee, and (ii) within [***]
days after the end of each Calendar Quarter in respect of Net Sublicense Fees, received in such quarter. Each such payment shall be accompanied by a statement of Net Sales and Net Sublicense Fees for the applicable Calendar Quarter and the
calculation of amounts payable hereunder, itemized on a Vaccine Composition-by-Vaccine Composition basis. 

  
 17. 

 6.8 SutroVax shall, during the Term and for [***] years thereafter, keep complete, true and
accurate records for the purpose of showing the derivation of all amounts payable to Sutro under this Agreement. Sutro shall have the right to access, inspect, copy, and audit such records at any time within [***] years following the end of the
Calendar Quarter for which such payment was due. The cost of any such inspection or audit shall be paid by Sutro; provided, however, if such audit uncovers an underpayment by SutroVax that exceeds [***] of the total amounts owed for the audited
period, then SutroVax shall pay the reasonable out-of-pocket costs of such inspection or audit. SutroVax shall have reciprocal rights as provided in this
Section 6.8 (including the allocation of costs) to audit Sutro with respect to amounts due to Sutro under Article 3 above. 
 6.9 All
payments by SutroVax to Sutro hereunder shall be made in United States dollars in immediately available funds by wire transfer from a bank account located in the United States to such bank account in the United States as may be designated in writing
by Sutro from time to time. Any late payments due hereunder shall bear interest at the rate of prime rate plus [***], as reported in The Wall Street Journal (U.S. Internet Edition at www.wsj.com), on the due date (or, if the due date is not a
business day, on the last business day prior to such due date), or the maximum allowable by law if less. 
 7. DILIGENCE 

7.1 General. SutroVax shall, on a continuing basis throughout the Term, exert Commercially Reasonable Efforts to develop, obtain
Regulatory Approvals for, and commercialize in the Territory, or to engage one or more Sublicensees to do so with respect to, Vaccine Compositions supplied or licensed to SutroVax hereunder. 

7.2 Diligence Milestones. Without limiting Section 7.1, SutroVax shall meet the diligence milestones set forth in Exhibit C,
directly or through one or more Affiliates or Sublicensees (except that the financial diligence milestone shall be achieved by SutroVax). In the event SutroVax fails to meet any diligence milestones within the applicable timelines set forth in
Exhibit C despite using its Commercially Reasonable Efforts to do so, due to delays which are out of the reasonable control of SutroVax (e.g., changes to the regulatory pathways or other regulatory delays), Sutro agrees to [***]. The Parties agree
that prior to the Amendment Effective Date SutroVax met the diligence milestones set forth in clauses 1, 2(a) and 2(b) of Exhibit C. 
 7.3
Reporting. SutroVax will provide Sutro with (a) semi-annual reports summarizing in reasonable detail the development and regulatory activities by SutroVax , its Affiliates and/or Sublicensees with respect to Vaccine Compositions, and
(b) annual commercialization reports summarizing in reasonable detail the commercialization activities with respect to Vaccine Compositions by SutroVax, its Affiliates and/or Sublicensees. Upon Sutro’s request, SutroVax will also provide a
copy of the then-applicable development and/or commercialization plan, and any other information reasonably requested by Sutro with respect to the development and/or commercialization of Vaccine Compositions under this Agreement. 

8. TERM AND TERMINATION 
 8.1 Term.
The term of this Agreement shall begin on the Effective Date and shall continue until terminated as provided herein (the “Term”). 

8.2 Mutual Termination for Breach. If either Party materially breaches any of the material terms, conditions or agreements contained in
this Agreement to be kept, observed or performed by it, the other Party may terminate this Agreement, at its option and without prejudice to any of its other legal or equitable rights or remedies, by giving the Party who committed the breach sixty
(60) days’ prior written notice, unless the notified Party shall have cured the breach within such 60-day period, subject to Section 14.5. 

  
 18. 

 8.3 SutroVax Termination Rights. 

(a) SutroVax may at its option terminate this Agreement upon at least sixty (60) days’ prior written notice to Sutro. 

(b) [Intentionally left blank] 

8.4 Sutro Termination Rights. 

(a) Sutro may terminate this Agreement if SutroVax or (subject to Section 15.2(d)) any of its Affiliates (directly or indirectly,
individually or in association with any other person or entity) brings an action or asserts a claim in any forum or administrative body that challenges the validity or enforceability of any claim of a Sutro Patent, immediately upon written notice.
In addition, Sutro may terminate this Agreement if a Sublicensee brings such an action or asserts such a claim, if such action or claim pertains to a Vaccine Composition (or expression thereof) within the scope of the Sublicense granted to such
Sublicensee, unless the Sublicensee withdraws such action or claim, or SutroVax terminates the applicable sublicense agreement with such Sublicensee, in each case within [***] days after written request by SutroVax to do so. Notwithstanding the
foregoing, subject for clarity to the [***] In-License, in the event that Sutro or any of its Affiliates or Sublicensees first initiates or participates in a legal proceeding against SutroVax or any of its
Affiliates or Sublicensees in which a Sutro Patent is asserted against SutroVax or any of its Affiliates or Sublicensees, then SutroVax or its Affiliates or Sublicensees shall have the right to participate in such action, including by challenging
such Sutro Patent, and no such challenge shall give Sutro a termination right under this Section 8.4(a). 
 (b) Sutro may terminate this
Agreement immediately upon notice in the event SutroVax fails to meet any of the diligence milestones set forth in Exhibit C, subject to any extensions thereof granted by Sutro under Section 7.2 or Section 8.5, as applicable, unless
(limited to diligence milestones other than the Financial Diligence Milestone) SutroVax cures such failure within [***] days after written notice from Sutro. 

(c) Sutro may terminate this Agreement immediately upon notice in the event SutroVax undergoes a Change of Control pursuant to which a Sutro
Competitor will (i) own a majority of SutroVax’s voting securities, (ii) merge into or consolidate with SutroVax, or (iii) purchase all or substantially all of SutroVax’s assets. 

8.5 [Intentionally left blank]. 

8.6 Survival. Termination of this Agreement for any reason shall not relieve either Party of any obligation accruing on or prior to such
termination, or which is attributable to a period prior to such termination, nor preclude either Party from pursuing any rights and remedies it may have under this Agreement, or at law or in equity, which accrued or are based upon any event
occurring prior to such termination. In addition: 
 (a) The provisions of Articles 1, 6 (with respect to payments accrued prior to the
effective date of termination), 8, 10, 12, 13, 14 and 15 shall survive termination of this Agreement for any reason; and 

  
 19. 

 (b) Sublicenses granted by SutroVax under Section 4.1(a) shall survive termination of
this Agreement for any reason, provided that the particular Sublicensee promptly agrees in writing to be bound by the terms and conditions of this Agreement, to the extent applicable to the scope of its sublicense and to the activities of the
particular Sublicensee. In such case, the Sublicensee shall be deemed the direct Party to this Agreement with respect to such terms (to such extent), and SutroVax and the Sublicensee shall promptly prepare and execute a direct license agreement
between them setting forth such terms. For clarity, notwithstanding the foregoing, the Sublicensee shall have no greater rights under this Agreement (or the agreement to be put in place between Sutro and the Sublicensee) than the Sublicensee had
under its sublicense agreement with SutroVax (and without limiting the foregoing, the Sublicensee’s rights shall be limited to the Vaccine Composition(s) covered by the sublicense agreement with SutroVax at the time of termination of this
Agreement, subject to Section 4.3), and Sutro shall have no greater obligations to such Sublicensee than it would otherwise have under this Agreement. Accordingly, the Sublicensee shall have no right to obtain Extract from Sutro or a CMO
hereunder, and Sutro shall have no obligation to the Sublicensee (or any other person) under Section 3.1 above; similarly, the provisions of Section 8.4(a) shall be applicable to the Sublicensee only as applicable to a Sublicensee under
the second sentence thereof. In addition, and notwithstanding the foregoing, Sutro shall have no obligation to the Sublicensee (or any other person) under Section 3.2, provided, however, that Sutro shall negotiate in good faith with the
Sublicensee the terms of a supply arrangement for Vaccine Compositions following termination of this Agreement, upon the Sublicensee’s written request. 

9. PATENT PROSECUTION AND ENFORCEMENT 
 9.1
Patent Prosecution. For clarity, the Parties acknowledge and agree that this Section 9.1(a) shall be subject to the terms of the [***] In-License with respect to Sutro Patents in-licensed thereunder. 
 (a) Sutro Patents. Subject to Sections 9.1(a)(i) and (ii) below,
Sutro shall be solely responsible for the Prosecution and Maintenance (as defined below) of the Sutro Patents at its own expense. 
 (i)
Notwithstanding Section 9.1(a) above, Sutro agrees to cooperate reasonably with SutroVax to seek and obtain Patents within the Sutro Patents, subject to SutroVax providing all data in possession of SutroVax and its Affiliates reasonably
necessary for such purpose: (1) that claim and contain disclosure supporting claims directed only to Vaccine Compositions generally, and to particular Vaccine Compositions specifically, their manufacture, and other subject matter within the
Vaccine Field; (2) that do not contain claims, and will not be amended to contain claims, directed to any subject matter other than as described in (1) above; and (3) that have coverage and scope reasonable and customary for Patents
of that type (“Vaccine Composition-Specific Patents”). Sutro shall have the [***] to Prosecute and Maintain the Vaccine Composition-Specific Patents, and SutroVax shall [***], provided that such [***]. Sutro will use Commercially
Reasonable Efforts to [***]. SutroVax may elect to [***], by giving Sutro [***] days prior written notice, in which case (A) [***]; and (B) [***]. 

(ii) Sutro agrees to keep SutroVax informed and updated, and the Parties shall cooperate reasonably with regard to the Prosecution and
Maintenance of the Vaccine Composition-Specific Patents and, to the extent they would cover a Vaccine Composition, its use or manufacture, other Sutro Patents. Without limiting the foregoing, before making any material filing or material response to
the applicable patent office with respect to any Vaccine Composition-Specific Patent or, to the extent it would cover a Vaccine Composition, its use or manufacture, other Sutro Patents, Sutro will provide SutroVax with the reasonable opportunity to
comment on the proposed filing or response. Sutro shall (1) [***] and (2) [***]. 

  
 20. 

 (iii) SutroVax may exclude from the definition of Sutro Patents any particular patent
application that would otherwise be within the Sutro Patents and is filed after the Amendment Effective Date (globally or in a particular country) upon written notice to Sutro, in which case such patent application shall cease to be a Sutro Patent
for all purposes of this Agreement, and SutroVax shall have no further rights or obligations under this Agreement. For clarity, as of the receipt of such notice by Sutro (i) the patent application(s) identified in such notice shall no longer be
included in the license granted in Section 4.1(a), and (ii) in no event shall a claim of such patent application(s) be deemed a Valid Claim. 

(b) Joint Vaccine Composition Patents. As between the Parties, notwithstanding Section 9.1(a) above, SutroVax shall have the [***]
to control the Prosecution and Maintenance of Patents claiming any inventions made jointly by the Parties in connection with the performance of the Research Plan or the production of Vaccine Compositions contemplated hereunder that pertain to
Vaccine Compositions generally, or particular Vaccine Compositions specifically, their manufacture, or other subject matter within the Vaccine Field (such Patents collectively referred to as “Joint Vaccine Composition Patents”),
provided that SutroVax (i) shall [***], and, [***], (ii) shall [***], and (iii) in the event Sutro wishes to[***], SutroVax shall [***]. For the avoidance of doubt, Sutro’s joint interest in the Joint Vaccine Composition Patents shall
be included in the Sutro Patents and shall be within the exclusive licenses granted to SutroVax for the Vaccine Field under Section 4.1(a). 

(c) SutroVax Platform Improvement Patents. SutroVax shall have the right to control the Prosecution and Maintenance of the SutroVax
Platform Improvement Patents at its expense, provided that SutroVax shall [***], and, [***]. SutroVax may elect, at its sole discretion, to discontinue prosecution of any SutroVax Platform Improvement Patent, and/or not to file any patent
applications that would otherwise be covered by a SutroVax Platform Improvement Patent, provided, in each case, that it provide timely notice of such decision to Sutro such that Sutro has the opportunity to continue at its cost the prosecution and
maintenance of the applicable SutroVax Platform Improvement Patent, with SutroVax’ consent (not to be withheld unreasonably). 
 (d) For
clarity, it is understood and agreed that, as between the Parties, inventions (and Patent rights therein) shall be owned by the inventor(s) thereof. Accordingly, as between the Parties, Sutro shall own all inventions solely made by Sutro’s
employees and contractors, and SutroVax shall own all inventions solely made by SutroVax’s employees and contractors, without exception, and nothing in this Agreement shall be deemed to assign ownership thereof to the other Party. 

(e) As used herein, “Prosecution and Maintenance” means, with respect to a Patent, the preparing, filing, prosecuting and
maintenance of such Patent, as well as re-examinations, reissues, requests for Patent term extensions and the like with respect to such Patent, together with the conduct of interferences, the defense of
oppositions and other similar proceedings with respect to the particular Patent; and “Prosecute and Maintain” shall have the correlative meaning. 

9.2 Patent Enforcement. For clarity, the Parties acknowledge and agree that this Section 9.2(a) shall be subject to the terms of
the [***] In-License with respect to Sutro Patents in-licensed thereunder. 

(a) Sutro Patents. 
 (i)
Notice. If either Party reasonably believes that any Sutro Patent is being infringed by a Third Party with respect to activities within the Vaccine Field or is subject to a declaratory judgment action arising from such activities (a
“Vaccine Field Infringement”), such Party shall promptly notify the other Party and the Parties shall discuss in good faith how best to respond. 

  
 21. 

 (ii) Vaccine Composition-Specific Patents and Joint Vaccine Composition Patents. As
between the Parties, SutroVax shall have the first right but not the obligation, itself or through a designee, to enforce any Vaccine Composition-Specific Patent and any Joint Vaccine Composition Patent, including (1) initiating or prosecuting
an infringement or other appropriate suit or action against such Third Party; and (2) defending any declaratory judgment action with respect thereto (the type of action described in each of (1) and (2), an “Enforcement
Action”). 
 (iii) Other Sutro Patents. As between the Parties, Sutro shall have the sole right to initiate and control any
Enforcement Action for Sutro Patents, other than the Vaccine Composition-Specific Patents and any Joint Vaccine Composition Patents, with respect to any Vaccine Field Infringement. 

(iv) Secondary Enforcement. Reasonably in advance of undertaking any Enforcement Action under Section 9.2(a)(ii), the Party with
the first right to undertake such Enforcement Action (the “Lead Enforcement Party”) will notify the other Party of its intent to take such action. In the event a Party does not initiate an Enforcement Action with respect to a
particular Patent for which it is the Lead Enforcement Party within [***] days of a request from the other Party to do so, such other Party shall have the right but not the obligation, itself or through a designee, to initiate and control such
Enforcement Action at its discretion and expense. 
 (v) Recoveries. Any amounts recovered by SutroVax or Sutro with respect to an
Enforcement Action under this Section 9.2(a) will be used first to reimburse the reasonable costs and expenses, including attorneys’ fees, incurred in bringing and maintaining the applicable Enforcement Action, then to satisfy any Third
Party obligations with respect to such recovery, and any remainder by SutroVax or Sutro shall be allocated between the Parties as follows: (a) if SutroVax is the enforcing Party: fifteen percent (15%) shall be paid to Sutro, and the remainder
shall be retained by SutroVax; (b) if Sutro is the enforcing Party: thirty percent (30%) shall be retained by Sutro, and seventy percent (70%) shall be paid to SutroVax; provided that if another patent controlled by SutroVax or its licensee is
also being enforced with respect to the same infringing party or product, then the portion retained by Sutro under (b) shall be
twenty-two-and-one-half percent (22.5%) (and 77.5% shall be paid to SutroVax). 

(b) SutroVax Improvement Patents. If either Party reasonably believes that any SutroVax Improvement Patent is being infringed by a Third
Party or is subject to a declaratory judgment action, such Party shall promptly notify the other Party. As between the Parties: 
 (i) Sutro
shall be solely responsible for the enforcement of the SutroVax Platform Improvement Patents outside the Vaccine Field, at its discretion and expense, and shall be entitled to retain all resulting recoveries. 

(ii) SutroVax shall be solely responsible for the enforcement of the SutroVax Platform Improvement Patents in the Vaccine Field, at its
discretion and expense, and shall be entitled to retain all resulting recoveries. 
 (c) Cooperation. If a Party brings an Enforcement
Action in accordance with this Section 9.2, the other Party shall reasonably cooperate, including, if required to bring such action, joining as a named party. The Parties shall keep one another informed of the status of their respective
activities regarding any Enforcement Action pursuant to this Section 9.2 or settlement thereof, and the Parties shall assist one another and cooperate in any such action at the other’s reasonable request. Neither Party shall have the right
to settle any Enforcement Action under this Section 9.2 in a manner that admits the invalidity or unenforceability of the other Party’s Patents, a Vaccine Composition-Specific Patent or a Joint Vaccine Composition Patent, without the prior
written consent of the other Party, which shall not be unreasonably withheld. 

  
 22. 

 9.3 Patent Term Extensions. Notwithstanding Section 9.1 above, but subject to
the terms of the [***] In-License with respect to Sutro Patents in-licensed thereunder, SutroVax shall have the exclusive right, itself or through a designee, to seek
patent term extensions and similar supplemental protections (“Patent Term Extensions”) as may be available with respect to Vaccine Composition-Specific Patents, Joint Vaccine Composition Patents and products incorporating Vaccine
Proteins; provided that SutroVax shall not have the right to seek or obtain any Patent Term Extensions with respect to any Sutro Patents, other than the Vaccine Composition-Specific Patents and any Joint Vaccine Composition Patents, without
Sutro’s consent. 
 9.4 SutroVax Name. 

(a) License Grant. Subject to the terms and conditions of this Agreement, Sutro hereby grants to SutroVax an exclusive license to use
the SUTROVAX trademark (“Mark”) in connection with the research, development, creation and commercialization of Vaccine Compositions in accordance with the Agreement, with the right to grant and authorize sublicenses in accordance
with Section 4.3 in the Territory during the Term of this Agreement. 
 (b) Acknowledgement of Ownership. SutroVax acknowledges
Sutro’s rights in and to the Mark and the SUTRO BIOPHARMA mark and that use of the Mark by SutroVax inures to the benefit of Sutro. Sutro shall file a trademark application for the Mark with the United States Trademark Office and other
jurisdictions worldwide as necessary to protect its rights in the Mark, in each case at SutroVax’s cost. SutroVax shall not oppose, seek to cancel or otherwise challenge Sutro’s ownership of the Mark, the SUTRO BIOPHARMA mark or their
validity. SutroVax shall not procure or attempt to procure any trademark registration for the Mark, the SUTRO BIOPHARMA mark or any other SUTRO-variant mark. 

(c) Quality Control. SutroVax agrees to use the Mark in conformance with Sutro’s trademark usage policies as communicated to
SutroVax from time to time. Sutro shall have the right, on a periodic basis and with reasonable notice, to inspect SutroVax’s packaging, advertisements, labels, marketing, and promotional materials, bearing the Mark to ensure that SutroVax is
in compliance with Sutro’s high quality standards. 
 (d) Notification of Third Party Claims. SutroVax shall promptly notify
Sutro of any claim, of which SutroVax is notified or otherwise becomes aware, by any third party alleging infringement, unfair competition, or similar wrongs relating to use of the Mark by SutroVax. 

(e) Enforcement Against Third Party Infringements. In the event that SutroVax believes or has reason to believe that any third party is
infringing upon the Mark, SutroVax shall promptly notify Sutro of all facts known to it relating to such infringement. Thereupon Sutro shall conduct its own investigation of such alleged infringement and [***]. SutroVax shall [***]. SutroVax shall
cooperate fully with Sutro in connection with the prosecution of any claim by Sutro against any such alleged infringer. 
 (f) Indemnities.
SutroVax shall indemnify and hold Sutro harmless from and against any claims, damages, liabilities, and costs (including reasonable attorneys’ fees) arising out of or in connection with any claim that SutroVax’s use of the Mark infringes
any trademark or other rights of any third party, subject to Section 12.3. 

  
 23. 

 (g) Termination. Upon termination of the Agreement, SutroVax shall immediately cease using
the Mark. 
 10. CONFIDENTIALITY 
 10.1
In the course of performing the transactions contemplated by this Agreement, whether before or after the Effective Date, a Party may disclose, or may have disclosed, to the other confidential information owned or controlled by the disclosing Party
(“Discloser’s Information”). The receiving Party will maintain in confidence the Discloser’s Information and will not use it for any purpose except for purposes authorized hereunder, and shall use Commercially Reasonable
Efforts to safeguard such information against disclosure to Third Parties, including without limitation employees and persons working or consulting for such Party that do not have an established, current need to know such information for purposes
authorized under this Agreement. This obligation of confidentiality does not apply to restrict use or disclosure by the receiving Party of technology, information or material that meet one or more of the following criteria: 

(a) they were properly in the possession of the receiving Party, without any restriction on use or disclosure, prior to receipt from the other
Party; 
 (b) they are at the time of disclosure hereunder in the public domain by public use, publication, or general knowledge; 

(c) they become general or public knowledge through no fault of the receiving Party following disclosure hereunder; 

(d) they are properly obtained by the receiving Party from a Third Party not under a confidentiality obligation to the disclosing Party hereto;
or 
 (e) they are independently developed by or on behalf of the receiving Party without the assistance of the confidential information of
the other Party. 
 Subject to the exceptions in (a)-(c) above, and notwithstanding the definition of “Discloser’s
Information” above, all data and results generated with respect to Vaccine Compositions from the performance of Research Plan or from Sutro’s manufacturing and supply of Vaccine Compositions under this Agreement shall be deemed
Discloser’s Information of SutroVax and the terms and conditions of this Agreement shall be deemed Discloser’s Information of both Parties. 

10.2 Each Party may use and disclose Discloser’s Information of the other Party as follows: 

(a) under appropriate confidentiality provisions substantially equivalent to those in this Agreement in connection with the performance of its
obligations or exercise of rights granted to such Party in this Agreement; and 
 (b) in communication with, whether existing or potential,
investors, acquirers, lenders, consultants, advisors (including financial advisors, lawyers and accountants), (sub)licensees, collaborators or service providers, in each case on a need to know basis under appropriate confidentiality provisions
substantially equivalent to those of this Agreement. 

  
 24. 

 (c) If a Party is required by judicial or administrative process to disclose the
Discloser’s Information of the other Party hereto, it shall promptly inform such other Party of the anticipated disclosure in order to provide it an opportunity to challenge or limit the disclosure obligations. Discloser’s Information that
is disclosed by judicial or administrative process shall remain otherwise subject to the confidentiality and non-use provisions of this Agreement, and, in disclosing the other Party’s Discloser’s
Information pursuant to law or court order, each Party shall take reasonable steps to ensure the continued confidential treatment of such Discloser’s Information; 

(d) Notwithstanding Section 10.2(c) above, a receiving Party may disclose Discloser’s Information of the other Party to governmental
entities as required by securities laws or rules of securities exchanges, provided that the receiving Party shall provide reasonable advance notice to the other Party of such disclosure and use Commercially Reasonable Efforts, to oppose such
disclosure or to request confidential treatment of such Discloser’s Information and, in any event, shall only disclose the minimum information, as reasonably determined by the receiving Party’s legal counsel, that is necessary to comply
with such requirements. 
 11. REPRESENTATIONS AND WARRANTIES 

11.1 Each Party represents and warrants to the other Party that it has the right to enter into this Agreement and grant the rights granted
hereunder. 
 11.2 Each Party represents and warrants to the other Party that it has and will at all times during the term of this Agreement
comply with all applicable laws in all material respects, including obtaining all necessary licenses, permits and authorizations necessary to perform this Agreement and to exploit any license granted to it hereunder, as now or hereafter required
under any applicable statutes, laws, ordinances, rules and regulations. 
 11.3 SutroVax represents and warrants to Sutro that it has not
prior to the Effective Date and shall not during the Term (i) have been debarred under Article 306 of the FDCA, 21 U.S.C. §335a(a) or (b), or any equivalent foreign or local law, rule or regulation; or (ii) use or employ in any
capacity related to the performance of Research Plan or manufacturing Vaccine Compositions or other activities hereunder any individual, corporation, partnership, or association which has been debarred under Article 306 of the FDCA, 21 U.S.C.
§335a(a) or (b), or any equivalent foreign or local law, rule or regulation. 
 11.4 Sutro represents and warrants to SutroVax that:

 (a) as of the Amendment Effective Date to the best of its knowledge, the practice of the Sutro Platform does not infringe on any Third
Party patents; 
 (b) as of the Amendment Effective Date, Exhibit B contains a complete and accurate list of all Sutro Patents, and Sutro and
its Affiliates do not own or control any other Patents covering the Sutro Platform, Extracts, Vaccine Compositions, or the manufacture or use thereof; 

(c) it has not granted prior to the Effective Date, and will not grant during the Term, rights to any Third Party that are inconsistent with
the rights granted to SutroVax hereunder; 
 (d) during the Term, it will not amend or terminate the [***]
In-License in any manner that would adversely affect SutroVax’s rights under this Agreement; and 

(e) it has not prior to the Effective Date and shall not during the Term (i) have been debarred under Article 306 of the FDCA, 21 U.S.C.
§335a(a) or (b), or any equivalent foreign or local law, rule or regulation; or (ii) use or employ in any capacity related to the performance of Research Plan or manufacturing of Extracts or Vaccine Compositions any individual,
corporation, partnership, or association which has been debarred under Article 306 of the FDCA, 21 U.S.C. §335a(a) or (b), or any equivalent foreign or local law, rule or regulation. 

  
 25. 

 12. INDEMNITIES 

12.1 SutroVax agrees to indemnify and hold harmless Sutro and its Affiliates and Sublicensees, and their respective agents, directors, officers
and employees and their respective successors and assigns (the “Sutro Indemnitees”) from and against any Third Party claim, suit, demand, investigation or proceeding brought by a Third Party (each a “Claim”) based on
(a) the development, use, manufacture, distribution or sale of any Vaccine Composition, including, but not limited to, [***], injury, damage, death or other consequence occurring to any person claimed to result, directly or indirectly, from the
possession, use or consumption of, or treatment with, any such product, whether claimed by reason of breach of warranty, negligence, product defect or otherwise, and regardless of the form or forum in which any such claim is made, or (b) any
breach of any representation, warranty, covenant or obligation of SutroVax in this Agreement. This indemnification shall not apply to the extent that the relevant Claim is due to the negligence or willful misconduct of a Sutro Indemnitee or a
material breach of any of Sutro’s representations, warranties, covenants and/or obligations under this Agreement or any supply agreement between the Parties as contemplated hereunder. 

12.2 Sutro agrees to indemnify and hold harmless SutroVax and its Affiliates, and Sublicensees, and their respective agents, directors,
officers and employees and their respective successors and assigns (the “SutroVax Indemnitees”) from and against any Claim any breach of any representation, warranty, covenant or obligation of Sutro in this Agreement. This
indemnification shall not apply to the extent that the relevant Claim is due to the negligence or willful misconduct of a SutroVax Indemnitee or a material breach of any of SutroVax’s representations, warranties, covenants and/or obligations
under this Agreement. 
 12.3 The obligation to indemnify pursuant to this Section 12 shall be contingent upon timely notification by
the indemnitee to the indemnitor of any claims, suits or service of process; the tender by the indemnitee to the indemnitor of full control over the conduct and disposition of any claim, demand or suit; and reasonable cooperation by the indemnitee
in the defense of the claim, demand or suit. No indemnitor will be bound by or liable with respect to any settlement or admission entered or made by any indemnitee without the prior written consent of the indemnitor. The indemnitee will have the
right to retain its own counsel to participate in its defense in any proceeding hereunder. The indemnitee shall pay for its own counsel except to the extent it is determined that (a) one or more legal defenses may be available to it which are
different from or additional to those available to the indemnitor, or (b) representation of two Parties by the same counsel would be inappropriate due to actual or potential differing interests between them. In any such case and to such extent,
the indemnitor shall be responsible to pay for the reasonable costs and expenses of the separate counsel retained to participate in the defense of the indemnitee, provided that such expenses are otherwise among those covered by the indemnitor’s
indemnity agreement hereunder. 
 12.4 At such time as any Vaccine Composition is being commercially distributed or sold or tested in
clinical trials by SutroVax or under its sponsorship and thereafter with respect to coverage tail periods consistent with prevailing industry norms, SutroVax shall, at its sole cost and expense, procure and maintain liability insurance coverage
appropriate, under prevailing industry norms, to the risk in marketing such Vaccine Composition(s) and shall cause Sutro and its Affiliates, licensors and employees to be added thereto as additional insureds. SutroVax will, following Sutro’s
reasonable request from time to time, present evidence to Sutro that the coverage is being maintained in accordance with the foregoing. In addition, SutroVax shall give Sutro, or require that its insurers agree to give Sutro, at least [***] days
‘ prior written notice of any material change in or cancellation of the insurance coverage. 

  
 26. 

 13. DISCLAIMER AND LIMITS OF LIABILITY 

13.1 THE WARRANTIES AND INDEMNITIES STATED IN THIS AGREEMENT ARE IN LIEU OF, AND THE PARTIES EACH DISCLAIM, ALL OTHER WARRANTIES, EXPRESS,
IMPLIED OR ARISING BY LAW, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. WIHTOUT LIMITING THE FOREGOING, SUTRO MAKES NO REPRESENTATION THAT ITS PERFORMANCE OF THE RESEARCH PLAN OR ANY OF
THE RESULTS THEREOF WILL BE SUCCESFUL. 
 13.2 Except for breaches of Section 4.1, 4.2 or 10, neither Party shall be liable under this
Agreement for any indirect, incidental, punitive, exemplary, special or consequential damages of any kind; provided, however, that this limitation will not reduce or affect either Party’s indemnification obligations under Section 12, and
shall not apply to willful or intentional breaches of this Agreement. 
 14. COMMUNICATION AND DISPUTE RESOLUTION 

14.1 Each Party will appoint an individual employed by it to serve as its “Principal Contact” for purposes of this Agreement. Either
Party may from time to time replace its Principal Contact with a different employee, but unless required due to events beyond its control, neither Party will replace its Principal Contact without at least [***] days prior notice to the other Party.
The two Principal Contacts shall communicate with each other regularly during the Term as the Parties may agree or as the Principal Contacts shall mutually determine to be useful. 

14.2 The Parties intend that, to the maximum extent practicable, they shall reach decisions hereunder cooperatively through discussions among
the Principal Contacts and by mutual consent of the Parties. In situations in which that does not occur, disputes or differences arising out of or in connection with this Agreement shall initially be referred for review by the Parties’
respective Senior Managements (as defined below). Such Senior Managements shall discuss the proposed dispute or difference, and shall meet with respect thereto if either of them believes a meeting or meetings are likely to be useful. If the Senior
Managements do not resolve the dispute or difference within [***] days (or such lesser or longer period as they may agree is a useful period for their discussions), then either Party may pursue its other available remedies, consistent with this
Agreement. As used herein, Sutro’s “Senior Management” means its then-current CEO, and SutroVax’s “Senior Management” means its then-current CEO. 

14.3 If the Senior Managements are not able to resolve such dispute referred to them under Section 14.2 within such [***] day period, then
subject to Sections 14.4 and 14.5, such dispute shall be resolved by final and binding arbitration as follows: The Parties shall select a mutually agreeable arbitrator who has significant relevant experience in the subject matter of the disputed
issue and no affiliation or pre-existing relationship with either Party. If the Parties cannot agree on an arbitrator within [***] days after the end of the [***] day period referred in Section 14.2,
either Party may request the Judicial and Mediation Services (“JAMS”) in San Francisco, CA to appoint an arbitrator on behalf of the Parties in accordance with the commercial arbitration rules of JAMS, and the proceeding shall be
conducted in accordance with JAMS rules. The arbitrator may decide any issue as to whether, or as to the extent to which, any dispute is subject to the arbitration and other dispute resolution provisions in this Agreement. The arbitrator must base
the award on the provisions of this Agreement and must render the award in a writing which must include an explanation of the reasons for such award. Judgment upon the award rendered by the arbitrator may be entered by any court having jurisdiction
thereof. The arbitrator’s fees and expenses shall be shared equally by the Parties, unless the arbitrator in the award assesses such fees and expenses against one of the Parties or allocates such fees and expenses other than equally between the
Parties. Each Party shall bear and pay its own expenses incurred in connection with any 

  
 27. 

 
dispute resolution under this Section 14.3. Notwithstanding the foregoing, either Party shall have the right, without waiving any right or remedy available to such Party under this Agreement
or otherwise, to seek and obtain from any court of competent jurisdiction any interim or provisional relief that is necessary or desirable to protect the rights or property of such Party, pending the selection of the arbitrator hereunder or pending
the arbitrator’s decision of the dispute subject to arbitration. 
 14.4 Notwithstanding Section 14.3, any dispute, controversy or
claim relating to the scope, validity, enforceability or infringement of any patent or of any trademark rights relating to any Vaccine Composition shall be submitted to a court of competent jurisdiction in the country in which such patent or
trademark rights were granted or arose. 
 14.5 In the event a Party disputes in good faith whether it is in breach of this Agreement and so
notifies the other Party in writing prior to the expiration of the applicable cure period set forth in Section 8.2 above, the cure period shall be tolled from the date of such notice. Promptly following the initiation of a proceeding under
Section 14.3 above with respect to such dispute, the arbitrator shall make a determination as to whether there is a good faith dispute as to the existence of a material breach of this Agreement. If the arbitrator determines that there is no
good faith dispute by the breaching Party as to the existence of a material breach of this Agreement, then the Agreement shall be deemed terminated, unless the breach is cured within the remainder (if any) of the cure period set forth in
Section 8.2 (after giving effect to the tolling of such cure period up to the date of such determination). If the arbitrator determines that there is a good faith dispute as to the existence of a material breach of this Agreement, the
non-breaching Party shall not have the right to terminate this Agreement unless and until it has been finally determined in accordance with Section 14.3 above that a breach actually occurred, and the breaching Party fails to cure such breach
within [***] days after such final determination (or such longer period as the arbitrator may specify). 
 15. MISCELLANEOUS 

15.1 Neither Party may assign or transfer this Agreement, including by merger, operation of law, or otherwise, without the other Party’s
prior written consent (which shall not be withheld unreasonably) except each Party may assign this Agreement without the other Party’s consent in the case of assignment or transfer to a Third Party that succeeds to all or substantially all of
the assigning Party’s business and assets relating to the subject matter of this Agreement, whether by sale, merger, operation of law or otherwise. Any attempted assignment by a Party in violation of this Section without the written consent of
the other Party will be null and void. Except as above limited, this Agreement is binding upon and will inure to the benefit of each of the Parties, its successors and assigns. Without limiting the foregoing, in the event that a Party is acquired,
the acquiring Party shall agree in writing to abide by the terms of this Agreement 
 15.2 In the event of a Change of Control of either
Party, notwithstanding Section 15.1 above: 
 (a) Patents, know-how and other intellectual
property that were controlled by the Acquirer prior to such Change of Control shall not for purposes of this Agreement be included within the Sutro Patents, the Sutro Know-How (including for clarity
information to be provided to SutroVax under Section 5.4), SutroVax Platform Improvements or the SutroVax Platform Improvement Patents. 

(b) Patents, know-how and other intellectual property that, following such Change of Control, are
developed, made or otherwise acquired or controlled by the Acquirer without material use of proprietary know-how of the Acquired Party or confidential Discloser’s Information of the other Party (such
proprietary know-how of the Acquired Party and confidential Discloser’s Information of the other Party, the “Segregated Technology”) shall not for purposes of this Agreement be included
within the Sutro Patents and the Sutro Know-How (in event of a Change of Control of Sutro) or the SutroVax Platform Improvements or SutroVax Platform Improvement Patents (in event of a Change of Control of
SutroVax); 

  
 28. 

 (c) In the event of a Change of Control of SutroVax, to the extent the Acquirer does not use
or exploit Segregated Technology pertaining to Extracts or rights licensed to SutroVax under this Agreement, Section 4.2(b) shall not apply to the Acquirer of SutroVax. In the event of a Change of Control of Sutro, to the extent the Acquirer
does not use Segregated Technology pertaining to Extracts, the restrictive covenants under Section 4.1(c), shall not apply to the Acquirer of Sutro. For clarity, Section 4.2(b) shall apply to an Acquirer of SutroVax only with respect to
activities of the Acquirer involving the use of Segregated Technology of SutroVax or rights licensed to SutroVax under this Agreement; and Section 4.1(c) shall apply to an Acquirer of Sutro only with respect to activities of the Acquirer
involving the use of Segregated Technology of Sutro. 
 (d) The Acquirer shall not be deemed an Affiliate for purposes Section 8.4(a)
above, but shall be deemed a Sublicensee (whether or not it has been granted a sublicense) for such purposes with respect to any action or claim that challenges the validity or enforceability of a Sutro Patent with respect to a Vaccine Composition
(or expression thereof). 
 (e) Notwithstanding the foregoing, if rights to Segregated Technology were granted to the Acquirer prior to the
Change of Control, then the use of such Segregated Technology in accordance with such grant (and consistent with the exclusive licenses granted under this Agreement) shall not be deemed use of Segregated Technology for purposes of this
Section 15.2. 
 (f) SutroVax’s obligation to pay Net Sublicense Fees to Sutro under Section 6.6 shall terminate upon a Change
of Control of Sutro. 
 (g) As used herein, “Acquirer” means the Third Party involved in the Change of Control, and any
Affiliate of such Third Party that was not an Affiliate of the Acquired Party immediately prior to the Change of Control; and “Acquired Party” means the Party that was the subject of such Change of Control, together with any entity
that was its Affiliate immediately prior to the Change of Control. 
 15.3 The Parties acknowledge and agree that all rights and licenses now
or hereafter granted under or pursuant to any Section of this Agreement, including the backup manufacturing license granted below, are rights to “intellectual property” as defined in Section 101(35A) of Title 11 of the United States
Code. In the event that a case under Title 11 is commenced by or against either Party (the “Bankrupt Party”), the other Party may elect to retain and may fully exercise all of its rights and elections under Section 365(n) of
Title 11 of the United States Code. 
 (a) In recognition that Sutro may become a Bankrupt Party, Sutro hereby grants to SutroVax a non-exclusive, royalty-free (subject to the terms of the Agreement, including, without limitation, SutroVax’s payment obligations under Article 6) license under Sutro Patents and Sutro Know-How, effective upon such time, if any, when Sutro has become a Bankrupt Party, to make or have made Extracts under Sutro Patents and Sutro Know-How solely for use in
manufacturing Vaccine Compositions for SutroVax, its Affiliates and Sublicensees solely for use in conjunction with the exercise, and within the scope, of the license granted in Section 4.1(a)(i), and Sutro shall, following such time, if any,
when Sutro has become a Bankrupt Party, transfer to SutroVax or its designee, the relevant processes, documents, and materials and other Know-How included in the Sutro Platform, as necessary or reasonably
useful for such manufacture and supply of Extracts. 

  
 29. 

 (b) During the Term, each Party shall create and maintain current copies to the extent
practicable of all intellectual property licensed hereunder to the other Party. Without limiting the Parties’ rights under Section 365(n) of Title 11, if a case under Title 11 is commenced by or against the Bankrupt Party, the other Party
shall be entitled to a copy of any and all such intellectual property and all embodiments of such intellectual property, and the same, if not in the possession of such other Party, shall be promptly delivered to it (i) before this Agreement is
rejected by or on behalf of the Bankrupt Party, within [***] days after the other Party’s written request, unless the Bankrupt Party, or its trustee or receiver, elects within [***] days to continue to perform all of its obligations under this
Agreement, or (ii) after any rejection of this Agreement by or on behalf of the Bankrupt Party, if not previously delivered as provided under clause (i) above. 

15.4 This Agreement incorporates the Exhibits referenced herein. This Agreement constitutes the entire agreement and supersedes all prior
agreements and understandings, both written and oral, between the Parties hereto with respect to its subject matter. For clarity, it is understood that this Agreement supersedes and replaces the Original Agreement in its entirety. 

15.5 All notices, requests or other communication provided for or permitted hereunder shall be given in writing and shall be hand delivered or
sent by confirmed facsimile, reputable courier or by registered or certified mail, postage prepaid, return receipt requested, to the address set forth on the signature page of this Agreement, or to such other address of which either Party may inform
the other in writing. Notices will be deemed delivered on the earliest of transmission by facsimile, actual receipt or [***] days after mailing as described herein. 

15.6 This Agreement may be amended, modified or waived only in a writing signed by the Party or Parties to be bound thereby. 

15.7 If any provision of this Agreement shall be held invalid, illegal or unenforceable, such provision shall be enforced to the maximum extent
permitted by law and the Parties’ fundamental intentions hereunder, and the remaining provisions shall not be affected or impaired. 

15.8 Nothing herein contained shall constitute this a joint venture agreement and, except as expressly set forth herein, nothing herein shall
constitute any Party as a partner, principal or agent of any other, this being an Agreement between independent contracting entities. Except as expressly set forth herein, no Party shall have the authority to bind any other in any respect whatsoever
to Third Parties. Except as provided herein, nothing contained in this Agreement shall be construed as conferring any right on any Party to use any name, trade name, trademark or other designation of any other Party hereto, unless the express,
written permission of such other Party has been obtained. 
 15.9 This Agreement has been submitted to the scrutiny of, and has been
negotiated by, both Parties and their counsel, and shall be given a fair and reasonable interpretation in accordance with its terms, without consideration or weight being given to any such term’s having been drafted by any Party or its counsel.

 15.10 This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of California, without
regard to any conflict of laws rules to the contrary. 
 15.11 This Agreement may be executed in two (2) or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile and other electronically scanned signatures shall have the same effect as their originals. 

  
 30. 

 IN WITNESS WHEREOF, the Parties hereto executed and acknowledged this Agreement as of the
date first written above. Each of the persons signing this Agreement affirms that he or she is duly authorized to do so and thereby to bind the indicated entity. 
  

									
	SUTRO BIOPHARMA, INC.	 		 	SUTROVAX, INC.
					
	By:	 	 /s/ William J. Newell
	 		 	By:	 	 /s/ Grant E. Pickering

	Name:	 	William J. Newell	 		 	Name:	 	Grant E. Pickering
	Title:	 	CEO	 		 	Title:	 	President & CEO

 Exhibit A 

Research Plan 
 {6 pages
omitted} 
 [***] 

 Exhibit B 

Sutro Patents 
 {22 pages
omitted} 
 [***] 

 Exhibit C 

Diligence Milestones 

[***] 

 Exhibit D 

Sutro Competitors 
 [***]

 Exhibit E 

[***] In-License Provisions 

SutroVax, Inc. (“SUTROVAX”) hereby agrees to be bound by the following terms and conditions from the [***] In-License, as a sublicensee of Sutro Biopharma, Inc. (formerly known as Fundamental Applied Biology, Inc., or “FAB”) (“SUTRO”). 

Sec. 1. The following provisions of the [***] In-License (Articles 9 and 10) are hereby included in
the Agreement (as if references to SUTRO were references to SUTROVAX), and [***] is hereby named as a third party beneficiary of such provisions: 

“9 WARRANTIES AND NEGATION OF WARRANTIES 

9.1 Warranties. [***] warrants and represents that (a) it has the right and authority to enter into this Agreement and to grant licenses
of the scope granted in this Agreement and (b) [***] has not previously granted any rights in the Licensed Patents other than the rights and licenses granted in the Pre-Existing Licenses and will not grant any
further rights in the Licensed Patents that are inconsistent with the rights and licenses granted to SUTRO herein. For purposes of clarity, SUTRO acknowledges that it has been made aware by [***] of the scope of the field of use of the Pre-Existing Licenses. 
 9.2 Negation of Warranties. Except as expressly set forth in this Agreement,
[***] makes no representations and extends no warranties of any kind, either express or implied. Among other things, [***] disclaims any express or implied warranty: 

(A) of merchantability, of fitness for a particular purpose, 

(B) of non-infringement or 

(C) arising out of any course of dealing. 

9.2 No Representation of Licensed Patent. SUTRO also acknowledges that [***] does not represent or warrant: 

(A) the validity or scope of any Licensed Patent, or 

(B) that the exploitation of Licensed Patent or Technology will be successful. 

10 INDEMNITY 
 10.1.
Indemnification. SUTRO will indemnify, hold harmless, and defend all [***] Indemnitees against any and all third party claims for death, illness, personal injury, property damage, and improper business practices arising out of the manufacture, use,
sale, or other disposition of the Licensed Patents or Licensed Products by SUTRO or any sublicensee, unless resulting from a claimed breach by [***] of its warranties or the gross negligence or willful misconduct of any [***] Indemnitee; provided
that: 
 (A) SUTRO receives prompt notice of any such claim, 

(B) SUTRO shall not be obligated to indemnify any [***] Indemnitee in connection with any settlement for any claim unless SUTRO
consents in writing to such settlement (which consent shall not be unreasonably withheld), and 

 (C) SUTRO shall have the first right to defend any such claim and, if SUTRO
elects to exercise such first right, the exclusive right to control the defense thereof. 
 Notwithstanding the foregoing, SUTRO shall have
no obligations for any third party claim or demand that may be the subject of this Section 10.1 if the [***] Indemnitee seeking indemnification makes any admission regarding such claim without the prior written consent of SUTRO, which consent
shall not be unreasonably withheld. 
 10.2. No Indirect Liability. Neither party shall be liable for any special, consequential, lost
profit, expectation, punitive or other indirect damages in connection with any claim arising out of or related to this Agreement, whether grounded in tort (including negligence), strict liability. contract, or otherwise arising out of or in
connection with solely this Agreement under any theory of liability; provided, however, that the foregoing shall not apply to any right of action for infringement, contributory infringement or inducement of infringement [***] may have under any
applicable law. Except as provided in Section 9.1, [***] shall not have any responsibilities or liabilities whatsoever with respect to Licensed Products. 

10.3. Workers’ Compensation. SUTRO will comply with all statutory workers’ compensation and employers’ liability requirements
for activities performed under this Agreement. 
 10.4. Insurance. During the term of this Agreement , SUTRO will maintain Comprehensive
General Liability Insurance, including Product Liability Insurance, with a reputable and financially secure insurance carrier to cover the activities of SUTRO and its sublicensees. Upon introduction of Licensed Product into humans, such insurance
will provide minimum limits of liability of [***] and will include all [***] Indemnitees as additional insureds. Such insurance shall be written to cover claims incurred, discovered, manifested, or made during or after the expiration of this
Agreement and must be placed with carriers with ratings of at least A- as rated by A.M. Best. Within [***] days of the introduction of Licensed Product into humans. SUTRO will furnish a Certificate of
Insurance evidencing primary coverage and additional insured requirements. SUTRO will provide to [***] days prior written notice of cancellation or material change to this insurance coverage. SUTRO will advise [***] in writing that it maintains
excess liability coverage (following form) over primary insurance for at least the minimum limits set forth above. All insurance of SUTRO will be primary coverage; insurance of [***] and [***] will be excess and noncontributory. Notwithstanding the
foregoing, if SUTRO proposes alternative coverage under this Section 10.4, [***] shall not unreasonably withhold its consent to such alternative coverage in lieu of the coverage detailed in this Section 10.4, so long as the proposed
coverage is reasonable and customary for the industry and reasonably protects [***]’s interests.” 
 Sec. 2. If the
[***] In-License is terminated, the applicable obligations with respect to the subject matter covered by the [***] In-License will be transferred to [***] or its
designee, and SUTROVAX will assume such obligations, and (to the extent it exercises any rights to such subject matter) SUTROVAX will make any payment thereby due under the [***] In-License by SUTRO directly
to [***] or its designee. For purposes of clarity, it is agreed that in the event the [***] In-License is terminated, [***] shall have audit rights vis-à-vis SUTROVAX and its Affiliates substantially similar to those set forth in Section 8.5 of the [***] In-License. 

Sec. 3. [***] is hereby named as a third party beneficiary of Section 8.4(a) of the Agreement. 

Sec. 4. Any sublicense granted by SUTROVAX under the Licensed Patents (as defined in the [***]
In-License) will not include the right to further sublicense (unless otherwise agreed in writing by [***] and SUTRO). 

 Exhibit F 

Technology Transfer 
 [***]

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 
 FIRST AMENDMENT TO AMENDED
AND RESTATED SUTROVAX AGREEMENT 
 This First Amendment (“Amendment No. 1”) to the Amended and Restated Sutrovax
Agreement dated as of October 12, 2015 (“Amended and Restated Agreement”) is made as of May 9, 2018 (“Amendment No. 1 Effective Date”), by and between Sutro Biopharma, Inc., having its
principal place of business at 310 Utah Ave, Suite 150, South San Francisco, CA 94080 (“Sutro”), and SutroVax, Inc., having its principal place of business at 353 Hatch Dr., Foster City, CA 94404 (“SutroVax”). Sutro
and SutroVax are each referred to herein individually as a “Party” and collectively as the “Parties”. 
 The Parties wish
to amend certain provisions of the Amended and Restated Agreement, and in consideration of the promises and covenants set forth herein, Sutro and SutroVax hereby agree as follows: 

1. Unless otherwise indicated, defined terms have the same meaning in this Amendment No. 1 as in the Amended and Restated Agreement. 

2. The following item shall be deleted in its entirety from Exhibit C: 

“[***]” 
 3. The Parties agrees and acknowledges that
SutroVax’s obligations under Section 7.2 of the Amended and Restated Agreement, including the remaining diligence milestones in Exhibit C, have been satisfied and, accordingly, the provisions of Sections 8.4(b) shall have no further force
or effect. 
 IN WITNESS WHEREOF, the Parties have caused this Amendment No. 1 to be executed by their duly authorized representatives as of the
Amendment No. 1 Effective Date. 
  

									
	SUTRO BIOPHARMA, INC.	  		  	SUTROVAX, INC.
					
	By:	  	 /s/ William S. Newell
	  	                                	  	By:	  	 /s/ Grant E. Pickering

	Name:	  	William S. Newell	  		  	Name:	  	Grant E. Pickering
	Title:	  	CEO	  		  	Title:	  	President & CEO

 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT
IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 
 SECOND AMENDMENT TO AMENDED
AND RESTATED SUTROVAX AGREEMENT 
 This Second Amendment (“Amendment No. 2”) to the Amended and Restated Sutrovax
Agreement dated as of October 12, 2015, as amended by that certain First Amendment to Amended and Restated SutroVax Agreement between the Parties dated May 9, 2018, (“Amended and Restated Agreement”) is made as of
May 29, 2018 (“Amendment No. 2 Effective Date”), by and between Sutro Biopharma, Inc., having its principal place of business at 310 Utah Ave, Suite 150, South San Francisco, CA 94080
(“Sutro”), and SutroVax, Inc., having its principal place of business at 353 Hatch Dr., Foster City, CA 94404 (“SutroVax”). Sutro and SutroVax are each referred to herein individually as a “Party”
and collectively as the “Parties”. 
 The Parties wish to amend certain provisions of the Amended and Restated Agreement, and in
consideration of the promises and covenants set forth herein, Sutro and SutroVax hereby agree as follows: 
 1. Unless otherwise indicated, defined terms
have the same meaning in this Amendment No. 2 as in the Amended and Restated Agreement. “Supply Agreement” means that certain Supply Agreement between the Parties dated May 29, 2018. 

2. The phrase “or by or for SutroVax pursuant to Section 15.3(a)” is hereby added after the phrase “or any CMO established or approved by
Sutro as described in Section 3.1” in Section 4.1(a) of the Amended and Restated Agreement. 
 3. The phrase “[***]” is hereby
deleted in Section 4.1(b) of the Amended and Restated Agreement and the following is hereby appended to the end of Section 4.1(b) of the Amended and Restated Agreement: 

“For further clarity, and without limiting the license granted in Section 15.3, the license granted in Section 4.1(a) does not
include the right to manufacture Extracts. Nothing in this Section 4.1 shall be deemed to limit SutroVax’s obligation to purchase SutroVax’s requirements of Extract from Sutro in Section 2.20 of the Supply Agreement. In addition,
manufacturing of Extracts in breach of Section 2.20 of the Supply Agreement shall be deemed a material breach of this Agreement and the Supply Agreement by SutroVax.” 

4. The phrase “[***]” is hereby deleted in Section 4.2(a) of the Amended and Restated Agreement. 

5. The phrases “In recognition that Sutro may become a Bankrupt Party,” and “, effective upon such time, if any, when Sutro has become a
Bankrupt Party,” are hereby deleted in their entirety in Section 15.3(a) of the Amended and Restated Agreement; the phrase “and Section 4.1(a)(ii)” is hereby added after the phrase “granted in
Section 4.1(a)(i)” in Section 15.3(a) of the Amended and Restated Agreement; and the following is hereby appended to the end of Section 15.3(a) of the Amended and Restated Agreement: 

“It is understood that the foregoing license shall not be deemed to limit SutroVax’s obligation to purchase SutroVax’s
requirements of Extract from Sutro in Section 2.20 of the Supply Agreement.” 

 6. The phrase “elects within [***] days to continue to perform all of its obligations under this
Agreement” in Section 15.3(b) of the Amended and Restated Agreement is hereby replaced with the phrase “within [***] days assumes this Agreement in accordance with 11 U.S.C. §§ 365(a) and 365(b)”. 

7. The following is hereby appended to the end of Section 15.3(b) of the Amended and Restated Agreement: 

“In the case where Sutro is the Bankrupt Party, the delivery shall include: copies of, or access to, the then-existing Sutro Know-How and Sutro Core Know-How that is reasonably necessary to enable SutroVax to exercise the rights granted in Section 15.3(a); reasonable on-site training at Sutro’s premises to enable SutroVax to implement such Sutro Know-How Sutro Core Know-How (subject to the
payment of reasonable fees to Sutro); and reasonable access during ordinary business hours to Sutro’s personnel knowledgeable of the Sutro Platform and Extract for technical advice with respect to the implementation of such Sutro Know-How and Sutro Core Know-How, whether by teleconference or in-person meeting (subject to the payment of reasonable fees to Sutro).
In addition, in the case where Sutro is the Bankrupt Party, if Sutro defaults in its disclosure obligation, SutroVax may obtain the Sutro Know-How or Sutro Core Know-How
from the first two CMOs qualified by Sutro to manufacture Extract, provided that, for clarity, Sutro has conducted a Process Transfer (as defined in the Supply Agreement) to each such CMO, and, such Sutro
Know-How and Sutro Core Know-How are made available by each such CMO to SutroVax per the terms of the agreement referenced below. Prior to executing its agreement with
each such CMO, Sutro will provide SutroVax a reasonable opportunity to comment on the provisions of such agreement that relate to SutroVax’s access to such Sutro Know-How and/or Sutro Core Know-How. Nothing in this Section 15.3 shall be deemed to limit SutroVax’s obligation to purchase SutroVax’s requirements of Extract from Sutro in Section 2.20 of the Supply Agreement.” 

8. The following new Section 15.12 is hereby added to the Amended and Restated Agreement: 

15.12 Each Party acknowledges that the other Party may likely suffer irreparable harm from such Party’s breach or threatened breach of
this Agreement and the other Party, in such cases, would therefore be entitled, without waiving any other right or remedy available to, to injunctive relief (including specific performance) without the requirement to post a bond, provided the waiver
by such Party of the other Party’s requirement to post a bond shall expire on the Change of Control of the other Party, and each party agrees that the arbitrator selected under Section 14.3 shall have the power to grant such injunctive
relief (or order specific performance). The Parties shall comply with any such injunctive relief (including specific performance) ordered by the arbitrator and agree that such order may, to the extent not precluded by applicable law, be enforceable
as a final award in any court of competent jurisdiction. 
 IN WITNESS WHEREOF, the Parties have caused this Amendment No. 2 to be executed by their
duly authorized representatives as of the Amendment No. 2 Effective Date. 

									
	SUTRO BIOPHARMA, INC.	  		  	SUTROVAX, INC.
					
	By:	  	 /s/ William S. Newell
	  	                                	  	By:	  	 /s/ Grant E. Pickering

	Name:	  	William S. Newell	  		  	Name:	  	Grant E. Pickering
	Title:	  	CEO	  		  	Title:	  	President & CEOEX-10.15

 Exhibit 10.15 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 
 SUPPLY AGREEMENT 

This SUPPLY AGREEMENT (“Supply Agreement”) is made as of May 29, 2018 (the “Effective Date”) by
and between SutroVax, Inc., a Delaware corporation having principal offices at 353 Hatch Dr., Foster City, CA 94404 (“SutroVax”) and Sutro Biopharma, Inc., a Delaware corporation, having principal offices at 310 Utah Ave, Suite 150,
South San Francisco, CA, 94080 (“Sutro”). SutroVax and Sutro may be referred to herein by name or individually, as a “Party” and collectively, as the “Parties.” 

BACKGROUND 
 A. Sutro
controls certain proprietary technology which permits cell-free expression of proteins, and Sutro licensed such technology to SutroVax under that certain Amended and Restated SutroVax Agreement dated as of October 12, 2015 (the “License
Agreement”). 
 B. SutroVax is a vaccine company primarily in the business of developing, manufacturing and marketing vaccine
products; and 
 C. SutroVax desires to purchase from Sutro, and Sutro desires to supply to SutroVax, the Extracts and Custom Reagents (as
defined below) upon the terms and subject to the conditions set forth herein. 
 NOW, THEREFORE, in consideration of the covenants,
conditions and undertakings hereinafter set forth, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows: 

AGREEMENT 
 ARTICLE 1

 DEFINITIONS/ INTERPRETATION 

For the purposes of this Supply Agreement, the following capitalized words and phrases shall have the following meanings: 

1.1 “Affiliate” means, with respect to either Party, any business entity controlling, controlled by, or under common
control with such Party. For the purpose of this definition only, “control” means (i) the possession, directly or indirectly, of the power to direct the management or policies of a business entity, whether through the ownership of
voting securities, by contract or otherwise, or (ii) the ownership, directly or indirectly, of at least fifty percent (50%) of the voting securities or other ownership interest of a business entity. Notwithstanding the above, in no event shall
Sutro (or any entity that would be an Affiliate of SutroVax solely because it is an Affiliate of Sutro) be deemed an Affiliate of SutroVax, or SutroVax (or any entity that would be an Affiliate of Sutro solely because it is an Affiliate of SutroVax)
an Affiliate of Sutro. 

 1.2 “Applicable Law” means all laws, ordinances, rules, rulings,
directives and regulations of any Governmental Authority that apply to the development, manufacture or supply of any Product or the other activities contemplated under this Supply Agreement, including (i) all applicable federal, state and local
laws, rules and regulations; (ii) the U.S. Federal Food, Drug and Cosmetic Act; (iii) regulations and guidelines of the FDA and other Regulatory Authorities, including cGMPs, if applicable; and (iv) any applicable non-U.S. equivalents of any of the foregoing, including guidelines of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (as amended from time
to time). 
 1.3 “cGMPs” means current good manufacturing practices and standards as set forth (and as amended from
time to time) in the current Good Manufacturing Practice Regulations of the U.S. Code of Federal Regulations, including 21 C.F.R. Sections 210 and 211, the European Community Directive 2003/94/EC and the ICH Harmonised Tripartite Guideline, Good
Manufacturing Practice Guides for Active Pharmaceutical Ingredients (Q7). 
 1.4 “Components” means any product or
material used in the Manufacture of the Products including the packaging materials. 
 1.5 “Extract” means
Sutro’s extract derived from strains of E. coli identified on Schedule 1 attached hereto, as may be amended from time to time in accordance with Section 12.7, and any new versions and improvements thereof that may be included
in Schedule 1 by written agreement of the Parties in accordance with Section 12.7. 
 1.6 “Facility” or
“Facilities” means the facilities where Product will be Manufactured as set forth in Schedule 1. Schedule 1 may be amended from time to time in accordance with this Supply Agreement to add or remove facilities. 

1.7 “FDA” means the United States Food and Drug Administration, or any successor agency thereto performing similar
functions. 
 1.8 “Fully Burdened Manufacturing Costs” means, with respect to a Product, Sutro’s costs of
manufacturing such Product, which manufacturing costs shall mean: (a) [***], and (b) [***], in each case to the extent directly allocated to and incurred in the manufacture by Sutro of such Product supplied to SutroVax, its Affiliates and
Sublicensees. Fully Burdened Manufacturing Costs shall not include any [***] and shall be calculated in accordance with the foregoing, GAAP and Sutro’s policies and procedures for its other products, in each case consistently applied (and such
plant operations and support services costs shall be allocated consistent with GAAP and other products of Sutro in that facility). 
 1.9
“Governmental Authority” means any court, agency, department, authority or other instrumentality of any nation, state, country, city or other political subdivision, including any Regulatory Authority. 

 1.10 “Manufacture” or “Manufacturing” means the
processes and procedures for the supply of the Products, including, (a) the supply and quality control of the Components; (b) the manufacture of the Products in bulk; (c) the Packaging and labeling of the Products; (d) the
quality control of the Products; and (e) the storage of the Products until shipment. 
 1.11 “Package” or
“Packaging” means packaging Product(s) in accordance with applicable Specifications. 
 1.12
“Person” means an individual, a corporation, a partnership, an association, a trust or other entity or organization, including a government or political subdivision or an agency thereof. 

1.13 “Price” means the price to be paid by SutroVax for each Product as set forth on Schedule 1 of this Supply
Agreement and as may be modified from time to time in accordance with Section 3.2. 
 1.14
“Product(s)” means the Extract and Custom Reagents. 
 1.15 “Custom Reagents” means Sutro’s
custom reagents identified on Schedule 1 attached hereto, and any new versions and improvements thereof that may be included in Schedule 1 by written agreement of the Parties in accordance with Section 12.7.

 1.16 “Regulatory Approval” means, with respect to a product, all approvals, licenses, registrations or
authorizations necessary to market and sell such product in a particular jurisdiction in the Territory (including applicable approvals of labeling, price and reimbursement for such product in such jurisdiction). 

1.17 “Regulatory Authority” means any federal, national, multinational, state, provincial or local regulatory agency,
department, bureau or other governmental entity, including the FDA, with authority over the development, Manufacture or commercialization (including approval of Regulatory Approvals) of any Product(s) in any jurisdiction in the Territory. 

1.18 “Regulatory Materials” means regulatory applications, submissions, notifications, communications, correspondence,
registrations, Regulatory Approvals and/or other filings made to, received from or otherwise conducted with a Regulatory Authority (including minutes of meeting with Regulatory Authorities) that are necessary or reasonably desirable to access in
connection with the development, manufacture, marketing, sale or other commercialization of any Product in a particular country or regulatory jurisdiction. Regulatory Materials include, without limitation, INDs, NDAs, BLAs, clinical trial
applications, marketing approval applications and applications for pricing approvals. 
 1.19 “Required Standards”
means Applicable Law, the Specifications, and the warranties given by Sutro in Section 7.3, provided that Required Standards shall not include compliance with cGMPs for Custom Reagents, Extract identified as “research
grade” Extract or Other Extracts. 

 1.20 “Specifications” means, with respect to a Product or applicable
Component thereof, all written product, regulatory, Manufacturing, release criterion, quality control and quality assurance procedures, processes, practices, standards, instructions and specifications applicable to the Manufacture of such Product or
Component, as agreed to by the Parties in writing from time to time. The initial Specifications for the Products are attached hereto as Schedule 2. 

1.21 “SutroVax CMO” means any contract manufacturer responsible for supplying or manufacturing a Vaccine Composition on
behalf of SutroVax or its Affiliates, selected in accordance with Section .2. 
 1.22 “Territory” means worldwide.

 1.23 “Third Party” means any Person other than SutroVax, Sutro, or their respective Affiliates. 

1.24 Additional Definitions. Each of the following terms shall have the meaning described in the corresponding Section of this Supply
Agreement indicated below: 

 

					
	Term	  	Section Defined	 
	Alternate Supplier	  	 	2.15	 
	Acceptance Period	  	 	4.2	 
	COA/COC	  	 	4.1	 
	CMC	  	 	6.2	 
	CMO	  	 	2.15	 
	Delivery Time Period	  	 	2.9.2	 
	Disputed Matter	  	 	11.4	 
	Drug Master File	  	 	6.2	 
	Effective Date	  	 	Preamble	 
	Force Majeure	  	 	12.3	 
	Forecast	  	 	2.3	 
	Indemnify	  	 	9.1.1	 
	Laboratory	  	 	4.3	 
	Latent Defect	  	 	4.2	 
	Liabilities	  	 	9.1.1	 
	License Agreement	  	 	Background	 
	Manufacturing Change	  	 	6.6	 
	MSDS	  	 	4.1	 
	Other Extract	  	 	2.16	 
	Party or Parties	  	 	Preamble	 

					
	Term	  	Section Defined	 
	Phase 3/Commercial Supply Agreement	  	 	2.14	 
	Q1, Q2 or Q3	  	 	2.3	 
	Quality Agreement	  	 	6.7	 
	Senior Management	  	 	11.2	 
	Short Dated Product	  	 	2.11	 
	Sutro	  	 	Preamble	 
	Sutro Activity Criteria	  	 	4.1	 
	Sutro Activity Test	  	 	4.1	 
	Sutro Indemnitees	  	 	9.1.2	 
	SutroVax	  	 	Preamble	 
	SutroVax Activity Criteria	  	 	4.1	 
	SutroVax Activity Test	  	 	4.1	 
	SutroVax Indemnitees	  	 	9.1.1	 
	Supply Agreement	  	 	Preamble	 
	Term	  	 	10.1	 
	Third-Party Claim	  	 	9.1.1	 
	Transfer Addendum	  	 	2.15	 
	Work Order	  	 	2.3	 

 
 

  
 1.25
Interpretation. The captions and headings to this Supply Agreement are for convenience only, and are to be of no force or effect in construing or interpreting any of the provisions of this Supply Agreement. Unless specified to the contrary,
references to Articles, Sections, Schedules or Exhibits mean the particular Articles, Sections, Schedules or Exhibits to this Supply Agreement and references to this Supply Agreement include all Schedules and Exhibits hereto. Unless context clearly
requires otherwise, whenever used in this Supply Agreement: (i) the words “include” or “including” shall be construed as incorporating, also, “but not limited to” or “without limitation;” (ii) the word
“or” shall have its inclusive meaning of “and/or;” (iii) the word “notice” shall require notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written
communications contemplated under this Supply Agreement; (iv) the words “hereof,” “herein,” “hereunder,” “hereby” and derivative or similar words refer to this Supply Agreement (including any Schedules
and 

 
Exhibits); (v) provisions that require that a Party or the Parties “agree,” “consent” or “approve” or the like shall require that such agreement, consent or approval
be specific and in writing; (vi) words of any gender include the other gender; (vii) words using the singular or plural number also include the plural or singular number, respectively; (viii) references to any specific law, or
article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement thereof; (ix) neither Party shall be deemed to be acting “under the authority” of the other Party; and
(x) any capitalized terms used and not defined in this Supply Agreement shall have the meaning set forth in the License Agreement. 

ARTICLE 2 
 SUPPLY

 2.1 Supply. Pursuant to the terms and conditions of this Supply Agreement, Sutro agrees that it will Manufacture the
Product(s) at the Facility(ies) for SutroVax and shall supply the Product(s) to SutroVax, its Affiliates, and any SutroVax CMO, for purposes of production of Vaccine Compositions (including development of processes for the production of Vaccine
Compositions), solely for non-clinical research purposes or in Phase I or Phase II clinical trials of such Vaccine Compositions.. 

2.2 Transfer of Product. Subject to Section 2.1, SutroVax may transfer Products to SutroVax CMOs selected by SutroVax and that are
reasonably acceptable to Sutro (the acceptance of which by Sutro not to be unreasonably withheld, conditioned or delayed) or previously approved by Sutro. 

2.3 Work Orders. From time to time, Sutro and SutroVax may execute one or more work orders, that describe the Product to be
Manufactured, the quantities of each Product to be Manufactured and supplied to SutroVax, the Price to be charged by Sutro (which shall be as set forth in Section 3.2) and paid by SutroVax for the Product, and the delivery date(s) for such
Product, (as executed, a “Work Order”). Each Work Order will expressly refer to this Supply Agreement, will form a part of this Supply Agreement, and will be subject to the terms and conditions contained herein. Sutro shall not
unreasonably withhold its agreement to any proposed Work Order requested by SutroVax. Sutro shall be obligated to execute proposed Work Orders requested by SutroVax (except with respect to Other Extracts) with respect to quantities in such proposed
Work Order for delivery at least [***] months after SutroVax’s request to the extent such quantities of Product (when added to the quantities of such Product in Work Orders previously agreed between the Parties for delivery within the one
(1) calendar year period prior to the requested delivery date of the proposed Work Order) are less than (a) [***] liters with respect to Extract or (b) a corresponding amount of each Custom Reagent to support use of [***] liters of
Extract. Sutro shall notify SutroVax as soon as possible if Sutro believes it will be unable to deliver Product in accordance with the applicable Work Order. Sutro’s providing of such notification shall not be interpreted in any manner as
relieving Sutro of its obligations under this Supply Agreement, nor shall it prevent SutroVax from pursuing any and all rights and remedies SutroVax may have based on Sutro’s failure to be able to deliver any Product in accordance with the
terms of this Supply Agreement. 

 2.4 Orders. 

2.4.1 Purchase Orders. Once both parties have executed a Work Order, SutroVax shall place a purchase order for the amounts of Products
to be purchased under such Work Order with delivery dates for such amounts consistent with such Work Order. Additionally, SutroVax may from time to time place purchase orders for additional quantities specifying requested delivery dates in
accordance with reasonable delivery schedules and lead times; in each case, as may be agreed upon from time to time by the Parties. Each purchase order placed by SutroVax shall specify the quantity of Product, destination(s) and requested delivery
dates. Sutro shall promptly accept all purchase orders with respect to the amounts of Products to be purchased under the applicable Work Order and shall accept or reject any amount in the purchase order in excess of the amounts of Products to be
purchased under the applicable Work Order and all other purchase orders for Product submitted by SutroVax in accordance with this Article 2 within [***] days from receipt of the order; provided however that Sutro shall use Commercially
Reasonable Efforts to accept such amounts and purchase orders. Accepted purchase orders may not be cancelled without the prior written agreement of both Parties except as set forth in Sections 2.5. Unless otherwise directed by SutroVax, Sutro
shall fill all accepted purchase orders for Product in accordance with the requested due dates as set forth in further detail in Section 2.9.2. 

2.4.2 No Conflicting Terms. The terms and conditions of this Supply Agreement shall be controlling over any conflicting terms and
conditions stated in SutroVax’s purchase order or Sutro’s invoice, confirmation or other standardized document. Any purchase order, order acknowledgement, invoice, proposal or other document which conflicts with or adds to the terms and
conditions of this Supply Agreement with respect to the Manufacture and supply of Product for the Territory is hereby rejected, unless the Parties mutually agree to the contrary in writing. 

2.4.3 Initial Order. Notwithstanding Section 2.3 or this Section 2.4, Sutro accepts
and agrees to fulfil the order previously placed by or on behalf of SutroVax (or to be placed by or on behalf of SutroVax, if no already placed) for the quantities of Product set forth in Schedule 3 by the delivery date set forth therein (the
“Initial Order”). 
 2.5 Cancellation. Notwithstanding anything herein to the contrary, SutroVax may not modify or
cancel purchase orders with respect to the amounts of Product to be purchased under the applicable Work Order, however SutroVax may modify or cancel other purchase orders (including amounts in a purchase order in excess of the amounts of Product to
be purchased under the applicable Work Order) for the Products provided that such modification or change is made further in advance of the originally requested delivery date than the required lead time, where the agreed required lead time for the
applicable purchase order has been evidenced in writing (including, for example, by email) between the Parties. 
 2.6 Delivery and Risk
of Loss. Sutro shall mark Product for delivery to the destination(s) specified by SutroVax. All shipments of Product(s) shall be delivered [***] (lncoterms 2010) Sutro Facility. Title and risk of loss and damage to the Product(s) shall remain
with Sutro until the Product(s) are delivered in accordance with the foregoing, at which time title and risk ofloss and damage to the Product(s) shall pass to SutroVax. SutroVax will arrange for shipping from Sutro’s Facility to the destination
specified by SutroVax at SutroVax’s cost and expense. 

 2.7 Packaging. Sutro shall provide the Product to SutroVax in Packaged form in
accordance with the Required Standards. 
 2.8 Conformance to Required Standards. Sutro shall Manufacture the Product(s) in accordance
with the Required Standards, as the same may be amended or supplemented from time to time. Each Party shall keep the other promptly and fully advised of any new requirements of the applicable Regulatory Authority or Applicable Law of which it
becomes aware and Sutro shall promptly implement such requirements as described in Section 6.6. 
 2.9 Supply and Delivery. 

2.9.1 Shortage. Sutro shall use reasonable efforts to promptly notify SutroVax in writing in the event that Sutro is unable or
anticipates that it will be unable to supply compliant Product in accordance with the requirements of this Supply Agreement, including the Quality Agreement and all Required Standards, and each Work Order. Sutro shall use Commercially Reasonable
Efforts to overcome any inability or anticipated inability to so supply compliant Product to SutroVax. 
 2.9.2 Delivery Delays.
Subject to Section 2.4.1 (including applicable lead times agreed upon in accordance with Section 2.4.1) Sutro shall make deliveries of Product(s) in accordance with Section 2.6, no more than [***] days before or [***] after the
delivery dates specified by SutroVax in the relevant purchase order (provided that such delivery date is in accordance with the applicable Work Order or such purchase order was otherwise accepted by Sutro) (the “Delivery Time
Period”). For any failure to supply compliant Product(s) in the later of the Delivery Time Period and the period ending [***] after the delivery date specified under the Work Order, without limiting SutroVax’s other remedies, subject
to this Section 2.9.2 and Section 9.3 (Limitation of Liability), Sutro shall be liable for any non-cancelable Third Party penalties, costs and expenses incurred by SutroVax as a result of
Sutro’s failure to supply Product(s) as aforesaid, subject to receipt by Sutro of appropriate documentary evidence of such penalties, costs and expenses to the extent such evidence of such amounts may be provided by SutroVax without breaching
SutroVax’s or its Affiliates’ duties of confidentiality to such Third Party (and provided that SutroVax shall use commercially reasonable efforts to (i) minimize or eliminate such penalties, costs and expenses and (ii) where
provision of such evidence to Sutro would result in a breach of such duties of confidentiality, to obtain the consent of the applicable Third Party to the provision of such evidence to Sutro). In the event that Sutro makes a Manufacturing Change and
is not able to Manufacture and supply Product in conformance with the Required Standards within [***] days of the delivery date identified on the applicable purchase order, Sutro shall Manufacture such Product without such Manufacturing Change. The
rights of SutroVax set forth in this paragraph are in addition to any other rights set forth in this Supply Agreement. 
 2.10
Allocation. Without limiting any other rights or remedies available to SutroVax, if the demand for a Product in aggregate exceeds available supply or Sutro otherwise concludes that it may be unable to supply a Product in accordance with the
requirements of this Supply Agreement in the quantities and within the time periods specified in each Work Order and the corresponding purchase orders that have been accepted by Sutro, Sutro shall immediately notify SutroVax of such shortfall (or
anticipated shortfall), and shall use Commercially Reasonable 

 
Efforts to procure Components and capacity adequate to meet accepted purchase orders and supply compliant Product in accordance with the requirements of this Supply Agreement. Sutro shall
allocate its available Components and manufacturing capacity to provide SutroVax with quantities of such Product at least equal to the greater of (a) [***] of the amount of Product (or products equivalent to Product) that Sutro allocates for
itself and its Affiliates (but in no event less than [***] liters of Extract per month and the minimum allocation volume set out in Schedule 1 of each Custom Reagent per month), provided that SutroVax demonstrates actual need for the applicable
quantities of Extract, and (b) the [***]. Without limiting the foregoing, if there is a shortage of supply of Product, Sutro shall provide Product to SutroVax for any quantities of Product ordered by SutroVax in accordance with the applicable
Work Order or purchase order in priority to any subsequent Third Party purchase orders, but not in priority to any Third Party purchase orders or other binding commitment placed before placement of the applicable SutroVax Work Order or purchase
order. 
 2.11 Short Dated Product. Sutro agrees to ship all Product(s) so that they are delivered to SutroVax and will remain
compliant with the Specifications for at least [***] months from the date of delivery in accordance with this Supply Agreement. 
 2.12
Subcontracting by Sutro. Sutro shall (a) ensure that any subcontractor or delegatee of Sutro’s obligations under this Supply Agreement has and maintains all appropriate qualifications; (b) enter into a quality agreement with each
such subcontractor and delegatee which terms are similar to the terms of the Quality Agreement between SutroVax and Sutro; and (c) be responsible for each subcontractor’s and delegatee’s performance hereunder (including performance or
non-performance by such subcontractor or delegatee that would constitute a breach of this Supply Agreement or such quality agreement if conducted by Sutro) as if Sutro were itself performing such activities.
Sutro shall not subcontract the Manufacture of Product to a Third Party without SutroVax’s prior consent other than to an Alternate Supplier as expressly set forth in Section 2.15. 

2.13 CMOs. Notwithstanding anything to the contrary in this Supply Agreement, SutroVax shall have the rights to purchase Available
Extracts and Extracts from CMOs (as defined in the License Agreement) to the extent provided in section 3.1 of the License Agreement. 

2.14 Phase 3/Commercial Supply Agreement. If requested by SutroVax in writing (which request shall not be made prior to [***]), the
Parties shall negotiate in good faith reasonable terms and conditions of an agreement for the supply by Sutro of the Products for the production of Vaccine Compositions for use in phase 3 clinical studies and for commercial purposes (“Phase
3/Commercial Supply Agreement”). The price for the Products Manufactured by Sutro under the Phase 3/Commercial Supply Agreement shall not exceed [***] of the Fully Burdened Manufacturing Cost thereof. If the Parties have not entered into
the Phase 3/Commercial Supply Agreement within [***] after SutroVax’s request to negotiate the Phase 3/Commercial Supply Agreement, upon either Party’s request by written notice to the other Party the terms and conditions of the Phase
3/Commercial Supply Agreement shall be determined by binding arbitration in accordance with the procedures set forth in Section 11.4. Upon the selection of one draft Phase 3/Commercial Supply Agreement by the arbitrator pursuant to
Section 11.4, unless SutroVax elects not to enter into such Phase 3/Commercial Supply 

 
Agreement by written notice thereof to Sutro within [***] days after such selection, the Parties shall execute the definitive Phase 3/Commercial Supply Agreement selected by the arbitrator (but
excluding, for clarity, any provision granting to SutroVax or its Affiliates or Sublicensees any right to obtain or use any Sutro Core Know-How); and if SutroVax elects to not enter into the Phase 3/Commercial
Supply Agreement selected by the arbitrator by providing notice thereof within such [***] day period, then neither Party shall be obligated to enter into the Phase 3/Commercial Supply Agreement. 

2.15 Qualification of Alternate Supplier. 

2.15.1 Transfer Addendum. 

(a) Transfer Addendum. Upon SutroVax’ written request, the Parties agree to negotiate in good faith an addendum to this Supply
Agreement setting forth the terms and conditions pursuant to which Sutro will conduct a Process Transfer to a Third Party contract manufacturer (“CMO”) and/or engage such CMO to establish Capacity to Manufacture Extract (as Process
Transfer and Capacity are defined below), in each case for the Manufacture and supply of such Extract for SutroVax’ (or its Affiliate’s or SutroVax CMO’s) use to manufacture Vaccine Compositions, consistent with the remainder of this
Section 2.15 (such addendum, a “Transfer Addendum”). As requested by SutroVax, this procedure may also be used in the event that SutroVax wishes Sutro to conduct a Process Transfer to a Third Party CMO in order to establish
Capacity to Manufacture Custom Reagents. In connection with such request, SutroVax shall provide to Sutro a description of the desired Process Transfer and/or Capacity, including timing and other requirements thereof. Such Transfer Addendum shall:

 (i) include a plan and budget for the conduct of the Process Transfer and/or establishment of such Capacity, which shall include amounts
charged by the CMO (as defined further below, the “Alternate Supplier”) to receive and conduct such Process Transfer and/or establish such Capacity, as well as reasonable FTE costs for Sutro personnel performing and managing
technology transfer activities in accordance with the Transfer Addendum· 
 (ii) require SutroVax to fund the costs incurred by Sutro
to conduct Process Transfer and/or establish such Capacity in accordance with such budget; 
 (iii) provide for initiation and completion of
the Process Transfer and establishment of Capacity as requested by SutroVax, to the extent possible; 
 (iv) to the extent requested by
SutroVax, be designed to enable the Alternate Supplier to Manufacture Extract of suitable quality for use in Phase 3 clinical trials and commercialization of a Vaccine Composition at a capacity to support SutroVax’ projected commercial
requirements for Extract (or other capacity identified by SutroVax in connection with the negotiation of the Transfer Addendum), as requested by SutroVax; 

(v) require the Parties to fully cooperate to verify that the Extract supplied by the Alternate Supplier meets the Specifications, to validate
the Manufacturing process implemented at the Alternate Supplier and to qualify the Alternate Supplier, in each case to supply Extract for SutroVax’ use in Phase 3 clinical trials and commercialization of a Vaccine Composition (collectively,
with respect to Capacity established, “Validating” such Capacity); 

 (vi) include mechanisms for keeping SutroVax fully informed, at scheduled intervals not to
exceed once per quarter, of the progress of the Process Transfer and establishing such Capacity, as applicable, including with respect to the anticipated date for qualifying the Alternate Supplier and any changes to such anticipated date; 

(vii) provide a right for SutroVax to modify the timing of or terminate the Process Transfer, Capacity or specified aspects thereof on
reasonable notice, subject to SutroVax’ agreement to bear any resulting termination or cancellation fees charged by the Alternative Supplier; and 

(viii) include a mechanism for Sutro to cooperate with SutroVax and keep SutroVax reasonably informed with respect to Sutro’s negotiation
of an agreement with a potential Alternate Supplier for a Process Transfer and/or establishment of Capacity, including with respect to pricing for Extract from the Alternate Supplier to Sutro and any commitments to purchase quantities of Extract
from the Alternate Supplier that SutroVax would be obligated to assume (e.g., in connection with establishing Capacity), if any, and require Sutro to obtain SutroVax’ approval (not to be withheld unreasonably) of the terms of such agreement
prior to entering into such agreement to the extent that the terms apply to SutroVax (it being understood that Sutro may redact any terms that are not relevant to SutroVax). 

(b) Scope. As used above, “Process Transfer” means a technology transfer of Sutro’s
know-how and information as is necessary or useful for the Third Party CMO to Manufacture in its own facilities Extract that meets SutroVax’ requirements, including any such information and know-how as would be needed for such CMO to scale up such Manufacture to the requested commercial volumes. To establish “Capacity” means that the CMO would take such actions as are necessary
(including validation and if necessary adapting or reserving existing facilities, establishing new facilities and/or procuring necessary equipment) to Manufacture Extract meeting SutroVax’ requirements for Phase 3 and commercial supply in such
quantities as SutroVax designates. It is understood that SutroVax may request that the Process Transfer and establishment of Capacity be undertaken in separate steps, for example by undertaking an initial Process Transfer to demonstrate the
CMO’s ability to Manufacture Extract, and then later establishing Capacity for Phase 3 and commercial supply, as requested by SutroVax in accordance with Section 2.15.1(a) (i.e., in separate requests). 

(c) Selection of Alternate Supplier. The “Alternate Supplier” will be selected by Sutro, provided that Sutro must select an
“Alternate Supplier” that is substantially similar to those CMOs identified on Schedule 2.15.1 hereto and provided further that SutroVax shall have the right to veto such selection based only on a genuine and material conflict of interest
between SutroVax and the Alternate Supplier. Additional CMOs may be added to Schedule 2.15.1 by Sutro with SutroVax’s approval (not to be withheld unreasonably). 

 (d) Alternate Supplier as Subcontractor. It is understood that the Alternate
Supplier established under the Transfer Addendum shall operate as a subcontractor of Sutro under this Supply Agreement and the Phase 3/Commercial Supply Agreement, and as such SutroVax will order from Sutro thereunder any Extract to be Manufactured
by such Alternate Supplier. Subject to the foregoing, the Transfer Addendum and the Phase 3/Commercial Supply Agreement will include reasonable and customary rights for SutroVax to conduct audits/inspections, site visits, quarterly meetings, each
such audit/inspection, site visit and quarterly meeting to be coordinated by Sutro and to occur in the presence of a representative for Sutro and SutroVax, in connection with the Alternate Supplier’s manufacture of Extract for supply to
SutroVax. For clarity, SutroVax shall not conduct any business discussions for the supply of Extract with the Alternate Supplier in a manner that induces the Alternate Supplier to breach its agreement with Sutro. Notwithstanding the foregoing, in
the event Sutro undergoes a Change of Control or Sutro permits any third party to acquire Extract directly from an Alternate Supplier established under the Transfer Addendum, then SutroVax shall thereafter have the right to establish a supply
agreement with and obtain supply of Extract directly from such Alternate Supplier. 
 (e) Quotations. Upon SutroVax’s request
(which request, for clarity, may be before a request to negotiate a Transfer Addendum), Sutro shall seek quotations from one or more Third Party CMO(s) for such a Process Transfer and/or establishment of such Capacity, in each case as requested by
SutroVax, and the Parties shall reasonably cooperate to establish requests for quotations for such purposes. 
 (f) Arbitration. If
the Parties have not agreed upon a Transfer Addendum within [***] after SutroVax’ request, upon SutroVax’ request by written notice to Sutro, the terms and conditions of the Transfer Addendum shall be determined by binding arbitration in
accordance with the procedures set forth in Section 11.4. For clarity, however, it is understood that a Transfer Addendum shall not include any provision granting to SutroVax or its Affiliates or Sublicens.ee s any right to obtain or use any
Sutro Core Know-How. 
 2.15.2 Source of Supply. It is understood that after the Alternate
Supplier is qualified, SutroVax shall have the right under this Supply Agreement and the Phase 3/Commercial Supply Agreement to specify whether Extract ordered from Sutro pursuant to this Agreement or the Phase 3/Commercial Supply Agreement will be
Manufactured at Sutro’s Facility or at the Alternate Supplier’s facilities (and to the extent Extract from the Alternate Supplier is ordered under this Supply Agreement or the Phase 3/Commercial Supply Agreement, the facility of the
Alternate Supplier shall be deemed a Facility for purposes of this Supply Agreement and the Phase 3/Commercial Supply Agreement). Notwithstanding the foregoing, to the extent the FDA and EMA have confirmed that Extract manufactured at Sutro’s
Facility and the Alternate Supplier’s Facility are interchangeable and can be supplied from either such Facility without any additional regulatory requirements or regulatory delay with respect to the applicable Vaccine Composition, and such
Extract otherwise meets SutroVax’ requirements, then with SutroVax’ consent (not to be withheld unreasonably) Sutro may supply Extract from either Sutro’s Facility or the Alternate Supplier’s Facility. 

2.15.3 Price. To the extent Sutro or its Affiliate Manufactures Extract supplied to SutroVax, the Price (per unit volume or unit weight)
under this Supply Agreement and the Phase 3/Commercial Supply Agreement for such Extract shall not exceed [***] of the Fully Burdened Manufacturing Costs of such Extract; and to the extent the Extract to be supplied to SutroVax is Manufactured by a
Third Party (including the Alternate Supplier), the Price to be 

 
charged to SutroVax under this Supply Agreement and the Phase 3/Commercial Supply Agreement for such Extract shall equal the amount Sutro paid such Third Party for such Extract (“OOP
Cost”) plus an amount reasonably calculated to cover Sutro’s FTE costs to procure and manage the relationship with such Third Party, such amount not to exceed [***] of the OOP Cost for such Extract. To the extent that Sutro or its
Affiliate receives any portion of the amounts paid to such Third Party to Manufacture Extract (e.g., as a profit share or otherwise), the Price to be charged SutroVax shall be the lesser of i) [***], or ii) [***]; in either case, [***]. For clarity,
Section 3.4 of the License Agreement shall apply with respect to the Alternate Supplier. 
 2.15.4 Sutro/Third Party use of Alternate
Supplier. Once the Alternate Supplier is qualified pursuant to this Section 2.15, SutroVax shall have the first right (as between SutroVax and Sutro or Third Parties supplied or authorized by Sutro) to obtain Extract Manufactured by the
Alternate Supplier up to the Capacity established pursuant to the Transfer Addendum for a period ending the later of [***] or [***], and provided SutroVax commits to [***] or [***]. 

2.16 Other Extracts. From time-to-time, subject to an
agreed-upon Work Order, SutroVax may place purchase orders for quantities of research grade extract derived from strains of E. Coli other than that set forth on Schedule 1 attached hereto (each an “Other Extract”). Sutro
shall use Commercially Reasonable Efforts to accept such purchase orders (and shall accept such purchase orders placed consistent with an agreed-upon Work Order) and manufacture and supply to SutroVax such Other Extracts. For the purpose of
calculating the Price for Other Extracts in accordance with this Section, the Price will be the cost of materials and Sutro’s labor at an FTE rate of [***] per year for Sutro laboratory scientists. Upon Sutro’s acceptance of a purchase
order for Other Extract, such Other Extract in such purchase order shall be deemed Extract for purposes of Sections 2.1, 2.2, 2.3, 2.4.1 (solely with respect to the last two sentences thereof), 2.5, 2.6, 2.7, 2.8, 2.9.1 , 3.1, 4, 5, 6, 7 and 9. 

2.17 Manufacture of Custom Reagents. For clarity, SutroVax may Manufacture Custom Reagents itself or obtain supply thereof through a
Third Party independent of this Supply Agreement and nothing in this Supply Agreement is intended to restrict SutroVax from doing so. Upon SutroVax’s request, and subject to the remainder of the terms of this Section 2.17, Sutro shall
(a) transfer to SutroVax or a contract manufacturer designated by SutroVax (which contract manufacturer is reasonably acceptable to Sutro, the approval of which shall not be unreasonably withheld, conditions or delayed by Sutro) as soon as
reasonably practicable the process to Manufacture each Custom Reagent and the items of Sutro Know-How reasonably necessary for SutroVax or its designee to Manufacture each Custom Reagent, including cell lines,
standard operating procedures, protocols, batch records, analytical method standard operating procedures and analytical method transfer protocols and (b) make Sutro Personnel reasonably available to SutroVax or its designee for scientific and
technical explanations and on-site support that may reasonably be requested by SutroVax or its designee to Manufacture the Custom Reagents; provided however, that SutroVax shall fully reimburse Sutro for all
documented time spent by Sutro’s personnel to perform such transfer (on an FTE basis, each such FTE charged at an annual rate of [***]) and out-of-pocket costs
incurred by Sutro in connection with all of the activities under the preceding sub-clauses (a) and (b), in accordance with a budget reasonably approved in advance by SutroVax. Upon such SutroVax request,
Sutro and SutroVax shall, within [***] days, agree on a scope of work for such transfer, including 

 
scale, timeline, estimated budget, and required materials; both parties shall use reasonable efforts to complete the transfer as soon as reasonably practical. If requested by SutroVax (including
if such request is prior to agreement on a scope of work), Sutro shall promptly transfer to SutroVax or its designee the cell lines, manufacturing instructions and analytical methods used for Manufacture of each Custom Reagent. For clarity, SutroVax
shall have the right to enter into an agreement directly with such designee for the Manufacture and supply of Custom Reagents directly to SutroVax, its Affiliates, and any SutroVax CMO and, upon SutroVax’s request, to the extent necessary,
Sutro shall authorize such designee to enter into such agreement with SutroVax and perform such activities. For further clarity, Sutro shall not be responsible for any damages resulting from delay or failure in establishing the processes for
Manufacture of Custom Reagents at SutroVax’s designee resulting from action or inaction on the part of the designee or to the extent beyond Sutro’s control. SutroVax shall have the right to obtain from such designee such items of Sutro
Know-How transferred to such designee and use such items in connection with the exercise of its rights pursuant to the License Agreement, including for the Manufacture of Custom Reagents and the management of such designee. SutroVax shall use such
Sutro Know-How transferred under this Section 2.17 (to the extent it is Discloser’s Information of Sutro and does not meet one or more the criteria in clause (a) through (e) of Section 10.1
of the License Agreement) only for the Manufacture of Custom Reagents or otherwise within the scope of rights and licenses granted SutroVax in the License Agreement. In case of such a transfer to SutroVax or its designee, SutroVax will share with
Sutro (i) the proposed process for manufacture of Custom Reagents through a Third Party so that Sutro may provide feedback and ensure that the process and Specifications are consistent with Sutro’s process, and (ii) all regulatory
submissions (including DMFs with respect to Custom Reagents) at least [***] days in advance of their intended date of submission to a Regulatory Authority in the Territory, and shall take into account Sutro’s feedback to ensure alignment with
Sutro’s regulatory submissions and Regulatory Approvals with respect to Custom Reagents. Following completion of the transfer set forth above, Sutro shall provide reasonable support for the use of Third Party Custom Reagents in conjunction with
Extract supplied by or on behalf of Sutro. In addition, Extract supplied by Sutro that conforms to the Required Standards when tested with Custom Reagents supplied by Sutro but not with Custom Reagents manufactured under this Section shall be deemed
to conform to the Required Standards and SutroVax may not reject such Extract as a result of such non-conformance to the Required Standards when tested with Custom Reagents. SutroVax shall not prevent Sutro
from separately contracting with the contract manufacturer for Manufacture of Custom Reagents for use on its own behalf or on behalf of other third parties. 

2.18 Sutro Core Know-How. Notwithstanding anything to the contrary, except as set forth in
Section 15.3 of the License Agreement, in no event shall SutroVax, its Affiliates or Sublicensees have the right to access any Sutro Core Know-How (as defined in the License Agreement), whether directly
from Sutro or its Affiliates or through a CMO or otherwise, and SutroVax, its Affiliates and Sublicensees shall not require, request or solicit any CMO to deliver any Sutro Core Know-How to SutroVax, its
Affiliates and/or its Sublicensees, and no agreement between any CMO and Sutro, its Affiliates and Subsidiaries shall contain any provision granting to SutroVax or its Affiliates or Sublicensees any right to obtain or use any Sutro Core Know-How.
Without limiting the foregoing, in the event any item of Sutro Core Know-How is delivered to SutroVax, its Affiliates and/or its Sublicensees (except as set forth in Section 15.3 of the License
Agreement), SutroVax, its Affiliates and Sublicensees shall immediately return such item to Sutro. Notwithstanding the foregoing, to the extent SutroVax or any of its Affiliates 

 
or Sublicensees is required by a Regulatory Authority (or Applicable Law) in the United States, Europe or Japan to confidentially disclose, as part of the applicable regulatory filings with
respect to a Vaccine Composition, any Sutro Core Know-How (for clarity, excluding any tangible embodiments of such Sutro Core Know-How other than information and
documentation), Sutro shall, upon SutroVax’s written request, confidentially disclose such Sutro Core Know-How as part of the applicable regulatory filings, subject to the payment obligations set forth in
Section 5.4 of the License Agreement. 
 2.19 Express Rights. Except as expressly set forth in this Supply Agreement, no rights
or licenses are granted to SutroVax under this Supply Agreement. 
 2.20 Extract Requirements. SutroVax agrees to purchase all its
requirements of Extract from Sutro in accordance with this Agreement, except to the extent SutroVax is allowed to purchase Extract from (a) Alternate Suppliers engaged by Sutro in accordance with Section 2.15 of this Agreement; (b) a
CMO engaged or established and authorized by Sutro under Section 3.l(d) of the License Agreement; or (c) a CMO authorized by Sutro under Section 3.l(e) of the License Agreement. Manufacturing of Extracts in breach of this
Section 2.20 shall be deemed a material breach of this Agreement and the License Agreement by SutroVax. 
 ARTICLE 3 

PRICING AND PAYMENT 

3.1 Invoices. Sutro shall invoice SutroVax at the time of each shipment of Product(s) for the Price for such shipment. SutroVax will
pay such invoices within [***] days of receipt of invoice (including all required documentation) by SutroVax. 
 3.2 Prices. The
Prices for the Products shall not exceed [***] of the Fully Burdened Manufacturing Costs of such Product at the time such Product is manufactured and shall be set forth in the applicable Work Order. Upon SutroVax’s request from time-to-time, Sutro shall disclose to SutroVax the then-current Price for Product. The Price for the Products as of the Effective Date is set forth in Schedule 1. 

3.3 Recordkeeping. During the Term and for [***] years thereafter, or for such longer period as may be required by Applicable Law, Sutro
shall prepare and retain, and shall cause its subcontractors to prepare and retain, accurate books and records related to transactions made pursuant to this Supply Agreement and Prices. Such records shall be made available for reasonable review,
audit and inspection upon reasonable notice and with reasonable frequency, upon SutroVax’s request for the purpose of verifying Sutro’s calculations of amounts due hereunder, the basis for such calculations (including Sutro’s
calculation of the Fully Burdened Manufacturing Costs) or payments and Sutro’s compliance with the terms and conditions of this Supply Agreement. Audits and inspections may be conducted by SutroVax’s own personnel or retained
consultant(s), subject to the confidentiality obligations set forth in this Supply Agreement. 
 3.4 Taxes. The Prices are exclusive
of all Taxes. SutroVax will pay all taxes and duties that are assessed by any national, federal, state or local governmental authority on SutroVax’s purchase or use of the Products, including, without limitation, sales, use, excise, value-added
and withholding taxes, but excluding any taxes based on Sutro’s income or gross receipts (collectively, “Taxes”). Sutro will separately identify all such Taxes on Sutro’s invoice. 

 ARTICLE 4 

PRODUCT TESTING 

4.1 Product Testing and Inspections. Each shipment of Product shall be accompanied by a certificate of analysis describing all current
requirements of the Specifications and results of tests performed on such Product and a certificate of conformity certifying that the quantities of Product supplied have been Manufactured, controlled and released according to the Required Standards
(“COA/COC”) as set forth in the applicable Quality Agreement (subject to SutroVax’s conduct of the SutroVax Activity Test to confirm Extract meets the SutroVax Activity Criteria). The COA/COC acceptance criteria for each
Product shall be set forth in the Specification for such Product. Two of the tests and corresponding COA/COC acceptance criteria for the Extract shall be the performance of a productivity (Activity) test of the applicable Sutro protein (the
“Sutro Activity Test” and “Sutro Activity Criteria”) and the performance of a productivity (activity) test of the applicable Vaccine Composition (the “SutroVax Activity Test” and “SutroVax
Activity Criteria”). Sutro shall perform the Sutro Activity Test to confirm that all shipments of Extract meet the Sutro Activity Criteria and SutroVax (or its designee) shall perform the SutroVax Activity Test to confirm that all shipments
of Extract meet the SutroVax Activity Criteria. Sutro will also provide SutroVax with Material Safety Data Sheets (“MSDS”) or an equivalent instrument recognized by the applicable Regulatory Authority as required for the Product(s),
and updates of the same as necessary. 
 4.2 Acceptance/Rejection of Non-Conforming Goods.
SutroVax or its designee shall have a period of [***] calendar days from the date of delivery of the Product(s) in accordance with Section 2.6 and the COA/COCs or the equivalent instrument recognized by the applicable Regulatory Authority for
such Product(s) (“Acceptance Period”), to inspect any shipment of Product(s) and conduct the SutroVax Activity Test to determine whether such shipment conforms to the Required Standards. If SutroVax determines that the Product(s) do
not conform to the Required Standards, it hall notify Sutro within the Acceptance Period, and, if requested by Sutro, SutroVax shall ship a sample of such non-conforming Product(s) to Sutro at Sutro’s
expense. SutroVax’s failure to notify Sutro of the non-conformity within the Acceptance Period will be deemed for purposes of this Supply Agreement to constitute SutroVax’s acceptance of such
shipment, provided, however, that such acceptance shall be subject to SutroVax’s right to reject Product(s) until [***] days from the delivery date of the applicable Product, in each case, due to discovery by SutroVax or SutroVax’s
Affiliates or designees that the applicable Product does not conform to the Required Standards and such non-conformance could not reasonably be discovered within the Acceptance Period (“Latent
Defects”) provided that SutroVax gives Sutro with written notice of such Latent Defect within [***] days of SutroVax or any SutroVax Affiliate or designee becoming aware of such defect. 

4.3 Disputes Regarding Conformance to Required Standards. If Sutro does not agree with SutroVax’s determination that Product fails
to conform to the Required Standards, then Sutro shall so notify SutroVax in writing within [***] days of its receipt of SutroVax’s notice of non-conformity with respect to such Product and (if requested)
Product sample. Sutro and SutroVax shall use reasonable efforts to resolve such disagreement as promptly as possible. 

 
Without limiting the foregoing, Sutro and SutroVax shall discuss in good faith mutually acceptable testing procedures pursuant to which both Sutro and SutroVax will
re-test a sample of the disputed Product to determine whether such Product meets the Required Standards. Notwithstanding the foregoing, in the event that Sutro and SutroVax are unable to resolve such
disagreement within [***] days of the date of the applicable rejection notice, either Party may submit a sample of the allegedly non-conforming Product for testing and a determination as to whether or not such
Product conforms to the Required Standards to an independent testing organization, or to a consultant of recognized repute within the United States pharmaceutical industry, in either case mutually agreed upon by the Parties (such organization or
consultant, the “Laboratory”), the appointment of which shall not be unreasonably withheld or delayed by either Party. The determination of the Laboratory with respect to all or part of any shipment of Product shall be final and
binding upon the Parties. The fees and expenses of the Laboratory making such determination shall be borne by Sutro, in the event that the Laboratory determines that the Product was non-conforming and by
SutroVax, in the event that the Laboratory determines that the Product did conform to the Required Standards. 
 4.4 Return and
Replacement of Non-Conforming Goods. Product that is either rejected by SutroVax as not meeting the Required Standards, or that is determined by the Laboratory not to meet such Required Standards, shall,
[***], be returned by SutroVax to Sutro, or destroyed pursuant to Applicable Law, at Sutro’s reasonable expense. Sutro shall replace any non-conforming Product(s) within the shortest possible time.
SutroVax shall have no responsibility to Sutro for the amounts invoiced for non-conforming Product(s), and shall be credited for any amounts paid, but shall pay Sutro the applicable Price for the replacement
Product(s) under the terms of Section 3.1. 
 ARTICLE 5 

INSPECTION 
 5.1
Right to Audit. During the Term and the [***] period thereafter, SutroVax or a SutroVax Affiliate may, during normal working hours and upon reasonable advance notice perform site audits and inspect, or request information relating to,
Sutro’s or its subcontractor’s Facilities and records directly or indirectly involved in the performance of this Supply Agreement or related to the Product(s). Such requests should be made in writing and Sutro will allow for such audits or
inspection to occur within [***] days from request (excepting for cause audits) for Sutro’s Facilities and within [***] days’ from request (excepting for cause audits) for Sutro’s subcontractor’s facilities. Reasonable advance
notice for audits for cause shall not require more than [***] advance notice. During such an inspection or request for information the inspectors may inquire about the progress of the work being carried out by Sutro or its subcontractor, and are in
particular but not exclusively authorized to: 
 5.1.1 Inspect the Facilities, documents and equipment used, or to be used, in the
Manufacture of the Product(s); 
 5.1.2 Verify the qualifications of the employees and subcontractors carrying out such work and their use of
the relevant equipment; 

 5.1.3 Evaluate all scientific techniques used by Sutro, its subcontractors and their
respective employees in the performance of this Supply Agreement and the procedures used in the creation and storage of samples of the Product(s), provided that nothing in this Section 5.1.3 shall require Sutroto disclose any Sutro Core Know-How; 
 5.1.4 Verify and evaluate information relating to the utilization of the Manufacturing
capacity of Sutro’s Facilities or its subcontractor’s Facilities; 
 5.1.5 Review correspondence, reports, filings and other
documents from Regulatory Authorities to the extent related to the Manufacturing activities hereunder; 
 5.1.6 Evaluate the implementation
of all Manufacturing and process changes made with respect to the Product, including pursuant to any corrective action plan; and 
 5.1.7
Ascertain compliance with Applicable Laws, the Specifications and this Supply Agreement. 
 5.2 Access. Sutro shall provide
SutroVax’s and its Affiliate’s and Sublicensee’s inspectors with access to its Facilities, and information related to such Facilities, in order that the inspectors may carry out the inspections or inquiries referred to in the
provisions of this Article 5. For the avoidance of doubt, neither SutroVax nor any of its Affiliates or Sublicensees (or their respective inspectors) shall have the right to observe the Manufacture of the Extract or be present at Sutro and
its subcontractors’ Facilities at such times when Extract is being Manufactured. Sutro shall use Commercially Reasonable Efforts to obtain from its subcontractors commitments similar to those contemplated in this Section 5.2. Audits and
inspections may be conducted by SutroVax’s own personnel or retained consultant(s), subject to the confidentiality obligations set forth in this Supply Agreement. 

5.3 Sutro Audits. Without limiting the foregoing; Sutro is responsible for auditing the facilities of the suppliers of Components, if
any, periodically, and Sutro agrees to provide SutroVax, upon SutroVax’s request with a current copy of the audit report of such facilities and to incorporate SutroVax’s comments with respect to any corrective action plan related to the
Product. 
 ARTICLE 6 

REGULATORY AND QUALITY RESPONSIBILITIES 

6.1 Regulatory Responsibilities. Sutro shall obtain and maintain any and all regulatory and governmental permits, licenses and
approvals that are necessary for Sutro to Manufacture the Product(s) for SutroVax or its Affiliates in accordance with the terms of this Supply Agreement and Applicable Law. As between the Parties, SutroVax shall have the sole responsibility for all
Regulatory Approvals of the Vaccine Compositions. 
 6.2 Right of Reference; Drug Master Files. Sutro shall (a) file Drug Master
File(s) for the Products with the FDA as requested by SutroVax, and with Regulatory Authorities in the European Union (including the United Kingdom) and Japan in accordance with timelines to be mutually agreed upon (such agreement not to be
unreasonably withheld by either Party) (provided at SutroVax’s request, Sutro shall do so within [***] of SutroVax’s request using 

 
Regulatory Filings that comprise versions of the DMF(s) filed with the FDA that have been reformatted to comply with EU and Japanese requirements), and (b) provide the appropriate
authorizations to such Regulatory Authority(ies) allowing the Regulatory Authority the right to review and SutroVax or its designee to reference such Drug Master File(s) in support of (and other Regulatory Materials, to the extent necessary to
support) an application for Regulatory Approval submitted by SutroVax (or its permitted designee) for any Vaccine Composition produced using the Product the subject of the applicable Drug Master File (it being understood that SutroVax, its
Affiliates· and Sublicensees shall not have access to the information contained in such Drug Master Files (or other confidential Regulatory Materials submitted for a similar purpose as a Drug Master File (e.g., a clinical trial application
for such purpose in the European Union)) as a result of such authorization and right to reference). Sutro shall file such Drug Master File in coordination with SutroVax’s efforts to file and prosecute the applicable regulatory filings to such
Regulatory Authority and Sutro shall be responsible, at SutroVax’s sole expense (subject to a budget reasonably approved in advance by SutroVax), for providing the applicable Regulatory Authorities with such additional data as they may request
(which may in some cases require Sutro to conduct additional studies), and for correcting any deficiencies of such Drug Master File identified by such Regulatory Authority, in each case in a reasonably prompt and efficient manner so as to prevent
any delay in obtaining Regulatory Approvals for any Vaccine Composition based on such Drug Master File. In addition, Sutro shall be responsible for maintaining such Drug Master File in accordance with applicable Laws as necessary to support filing
and prosecuting the applicable regulatory filing(s) and obtaining and maintaining the applicable Regulatory Approval(s) for Vaccine Compositions produced using the Products. For further clarity, to the extent Sutro discloses. Sutro Know-How to SutroVax, SutroVax shall have the right to include (and authorize the inclusion of) such Sutro Know-How in Regulatory Materials to the extent it is necessary or
useful for the purpose of obtaining Regulatory Approval of a Vaccine Composition. Sutro’s obligations under this Section 6.2 shall [***]. Sutro shall cause its personnel to record time spent performing such activities to a job code
specific to such activities. For purposes of this Article 6 “Drug Master File” or “DMF” means a submission to a Regulatory Authority of information concerning the chemistry, manufacturing and controls
(“CMC”) of the Products to permit such Regulatory Authority to review this information in support of any application for Regulatory Approval for a product submitted by a party that has been granted a right to reference such
submission without disclosing the contents of such submission to such party. Sutro shall file DMF(s) for the Products with other Regulatory Authorities in the Territory in accordance with the terms and conditions of the Phase 3/Commercial Supply
Agreement referenced in Section 2.14 (and, for clarity, shall file DMF(s) for the Products with Regulatory Authorities in the European Union (including the United Kingdom) and Japan as necessary to comply with the requirements of such
Regulatory Authorities, to the extent not filed under this Supply Agreement). 
 6.2.1 Compliance. Subject to the foregoing, Sutro
shall provide the information set forth under this Section 6.2 in a timely manner and compliant with the reporting requirements of the Regulatory Authorities. 

 6.2.2 Safety Data. Each Party understands and acknowledges that the other Party and
its Affiliates and respective licensees or sublicensees may need to access and utilize and include certain safety data (e.g., adverse event reports) pertaining to product made using Products that is generated or received by such Party and its
Affiliates and respective licensees or sublicensees in its Regulatory Materials in its respective Territory as required by applicable Laws. Each Party shall have the right to share any and all such safety data generated by the other Party or the
other Party’s Affiliates or licensees or sublicensees with its Affiliates and Third Parties (including its licensees and sublicensees) as permitted under section 10.2 of the License Agreement. 

6.2.3 Cooperation. Each Party agrees to (i) make its personnel reasonably available at their respective places of employment to
consult with the other Party on issues related to the activities conducted in accordance with this Article 6 or otherwise relating to the development of the Products or Vaccine Compositions and thereafter in connection with any request from any
Regulatory Authority, including with respect to regulatory, scientific, technical and clinical testing issues, or otherwise, throughout the Term, and (ii) otherwise provide such assistance as may be reasonably requested by the other from time-to-time in connection with the activities to be conducted under this Article 6 or otherwise relating to the development of the Vaccine Compositions or Products. 

6.3 Recalls. Each of SutroVax and Sutro will immediately inform the other in writing if it believes one or more lots of any Product(s),
or any products made by Sutro or its licensees using the Products (to the extent such products are made using Products from the same batch provided to SutroVax), or any Vaccine Compositions should be subject to recall from distribution, withdrawal
or some other field action, or that potential adulteration, misbranding, and/or other issues have arisen that relate to the safety or efficacy of such Product. SutroVax shall have the final decision-making authority as to any such recall or field
action and the sole right to initiate any such recall or field action with respect to Vaccine Compositions made using the Products. Sutro shall cooperate in the conduct of any recall or field action with respect to the Vaccine Compositions as
reasonably requested by SutroVax. In the event it is determined that such a recall resulted from a breach by either Party of any of its representations, warranties, duties or obligations under this Supply Agreement, such Party shall be responsible
for the costs of the recall and shall reimburse the other Party as necessary; provided that if both Parties share responsibility with respect to such recall, the costs shall be shared in the ratio of the Parties’ contributory responsibility.

 6.4 Retention of Samples. Sutro shall prepare and retain, and shall cause its subcontractors to prepare and retain, such samples
and records in respect of the Product(s) and the Manufacture thereof as are required by Applicable Law (including, as applicable, cGMPs). 

6.5 Regulatory Authority Inspections and Correspondence. Sutro shall permit Regulatory Authorities to conduct such inspections of any
Facility at which any of the Manufacturing activities relating to the Product(s) are performed, as such Regulatory Authorities may request, including pre-approval inspections,· and shall cooperate with
such Regulatory Authorities with respect to such inspections and any related matters, in each case that is related to the Manufacture of Product(s). Sutro shall give SutroVax or its Affiliates prior written notice of any such inspections, and shall
keep SutroVax informed about the results and conclusions of each such regulatory inspection, including actions taken by Sutro to remedy conditions cited in such inspections. Sutro shall provide SutroVax with copies of any written inspection reports
issued by anyRegulatory Authority and all correspondence between Sutro and any Regulatory Authority with respect thereto, including any notices of observation and all related 

 
correspondence, in each case relating to the Product(s) or its Manufacture or to general manufacturing concerns (e.g., facility compliance or the like) that are reasonably likely to impact the
Product(s) to the extent such general manufacturing matters would be reasonably expected to have a material effect on the manufacture of Vaccine Compositions; provided that Sutro may redact from any such report and correspondence any Sutro Core Know-How and any information subject to an obligation of confidentiality to a Third Party. In addition, Sutro agrees to promptly notify and provide SutroVax copies of any material request, directive, or other
written communication to or from Regulatory Authorities related to the Product or its Manufacture that would reasonably be expected to have a material effect on the manufacture of Vaccine Compositions (it being understood that SutroVax, its
Affiliates and Sublicensees shall not have access to Sutro Core Know How (which Sutro may redact from such reports or correspondence provided to SutroVax) or Sutro’s Drug Master Files or other confidential Regulatory Materials submitted for a
similar purpose as a Drug Master File). Sutro shall provide SutroVax with a copy of the applicable portion of any correspondence made by Sutro to a Regulatory Authority for review and comment prior to submission to the applicable Regulatory
Authority solely to the extent such correspondence made by Sutro is related to SutroVax or is in response to a request, directive or correspondence from the applicable Regulatory Authority regarding SutroVax or a Vaccine Composition (e.g., in
response to a report regarding a pre-approval inspection for SutroVax). Sutro will consider in good faith any comments received from SutroVax within the time period indicated by Sutro (which shall not be less
than [***], to the extent consistent with the require timeline for Sutro’s response) with respect to any matter that relates to SutroVax. In addition, Sutro shall notify SutroVax of any occurrences or information that arise out of Sutro’s
Manufacturing activities that have, or could reasonably be expected to have, adverse regulatory compliance or reporting consequences concerning any Product(s) or which might otherwise be reasonably expected to adversely affect the supply by Sutro of
Product(s) to SutroVax. 
 6.6 Changes or Modifications in Manufacturing Activities. Sutro shall not make any changes to the
Specifications, processes, Facilities, raw materials, raw material suppliers or any other item that would affect the Manufacturing activities related to the Product (a “Manufacturing Change”) that (a) would require a change to
the applicable Drug Master File, (b) would be reasonably expected to cause SutroVax to be materially delayed obtaining any Regulatory Approval with respect to Vaccine Compositions or (c) causes the Product to not meet the Specification
therefor (including the Activity Test with respect to Extract); without SutroVax’s prior written consent (not to be unreasonably withheld, conditioned or delated). Notwithstanding the foregoing, Sutro shall promptly make and implement such
changes as are required by Applicable Law provided that, prior to implementation, Sutro shall provide notice thereof to SutroVax and confer with SutroVax with respect to its timelines, estimated effect on Price and other issues regarding such
implementation. Sutro shall provide SutroVax at least [***] days’ written notice prior to implementing any Manufacturing Change. Sutro shall not make any change to the Specification for a Product without SutroVax’s prior written consent.
In addition, SutroVax shall have the right to request changes in or modifications to the Specifications and Sutro will consider in good faith any such requested changes or modifications. All such changes or modifications shall be documented in
writing and shall be signed by an authorized representative of SutroVax and Sutro. If such changes or modifications result in a material change in Sutro’s Manufacturing costs or lead times, the Parties shall agree upon an appropriate adjustment
to the Price or in the delivery schedules, as the case may be, for Product(s) to be provided by Sutro hereunder. Sutro shall promptly implement any agreed upon changes to the Specifications. 

 6.7 Quality Agreement. As soon as reasonably practicable after the Effective Date,
the Parties shall enter into a quality agreement governing Sutro’s supply of Products (the “Quality Agreement”), which Quality Agreement shall include the Specifications for the Product(s) consistent with the Specifications set
forth in Schedule 2. Accordingly, to permit the Quality Agreement to be finalized within such period, Sutro shall provide SutroVax or its designee access to Sutro’s Facilities and records to enable SutroVax or its designee to complete an audit
pursuant to Section 5.1 within [***] days after the Effective Date. 
 ARTICLE 7 

REPRESENTATION AND WARRANTIES 

7.1 SutroVax Warranties and Representations. SutroVax represents and warrants the following: 

7.1.1 SutroVax is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware. 

7.1.2 SutroVax has all requisite power and authority to enter into this Supply Agreement. The person signing this Supply Agreement has the
necessary corporate authority to legally bind SutroVax to the terms set forth herein. 
 7.1.3 SutroVax’s execution of this Supply
Agreement and performance of the terms set forth herein will not cause SutroVax to be in conflict with or constitute a breach of its organizational documents nor any other agreement, court order, consent decree or other arrangement, whether written
or oral, by which it is bound. 
 7.1.4 SutroVax’s execution of this Supply Agreement and performance hereunder are in, and will be in,
compliance with any Applicable Law in all material respects. 
 7.1.5 This Supply Agreement is its legal, valid and binding obligation,
enforceable against SutroVax in accordance with the terms and conditions hereof, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally
or by the principles governing the availability of equitable remedies. 
 7.2 Sutro Warranties and Representations. Sutro represents
and warrants the following: 
 7.2.1 Sutro is a corporation duly organized, validly existing and in good standing under the laws of the State
of Delaware. 
 7.2.2 Sutro has all requisite power and authority to enter into this Supply Agreement and has the requisite skill, knowledge,
staffing, financial resources, capacity and ability to carry out its obligations hereunder. The person signing this Supply Agreement has the necessary authority to legally bind Sutro to the terms set forth herein. 

 7.2.3 Sutro’s execution of this Supply Agreement and performance of the terms set forth
herein will not cause Sutro to be in conflict with or constitute a breach of its organizational documents nor any other agreement, court order, consent decree or other arrangement, whether written or oral, by which it is bound. 

7.2.4 Sutro’s execution of this Supply Agreement and performance hereunder are in, and will be in, compliance with any Applicable Law in
all material respects. 
 7.2.5 Sutro has and will maintain throughout the Term all permits, licenses, registrations and other forms of
governmental authorization. and approval as required by Applicable Law in order for Sutro to execute and deliver this Supply Agreement and to perform its obligations hereunder in accordance with all Applicable Law. 

7.2.6 as of the Effective Date, to the best of Sutro’s knowledge, the practice of the Sutro Platform, including the use of the Products,
does not infringe any Third Party patents. 
 7.2.7 7.2.7 Sutro is not debarred and Sutro has not and will not use in any capacity the
services of any person debarred under subsection 306(a) or (b) of the U.S. Generic Drug Enforcement Act of 1992, or other Applicable Law, nor have debarment proceedings against Sutro or any of its employees or permitted subcontractors been
commenced. 
 7.2.8 This Supply Agreement is its legal, valid and binding obligation, enforceable against Sutro in accordance with the terms
and conditions hereof, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally or by the principles governing the availability of
equitable remedies. 
 7.2.9 As of the Effective Date, there are no claims, judgments or settlements against or owed by Sutro or its
Affiliates, or pending or, to the best of Sutro’s knowledge, threatened claims or litigation, relating to the Product(s). 
 7.3
Product Warranties. Sutro represents and warrants that: 
 7.3.1 Sutro’s Facility and all Product (as delivered in accordance with
Section 2.1 and until the expiration date thereof) supplied hereunder (and the Manufacture thereof) shall comply with this Supply Agreement, all Applicable Law (including cGMPs, if applicable),·be free from defects in material and
workmanship, and meet all Specifications. 
 7.3.2 Title to all Product(s) provided under this Supply Agreement shall pass to SutroVax as set
forth in Section 2.6, free and clear of any security interest, lien, or other encumbrance. 
 7.4
Disclaimer. EACH PARTY AGREES AND ACKNOWLEDGES THAT, EXCEPT AS SET FORTH IN THIS ARTICLE 7, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND WHATSOEVER, IMPLIED OR STATUTORY, AND EACH PARTY HEREBY EXPRESSLY DISCLAIMS ALL
REPRESENTATIONS AND WARRANTIES, IMPLIED OR STATUTORY, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AGAINST NON-INFRINGEMENT OR THE LIKE, OR ARISING FROM COURSE OF
PERFORMANCE. 

 ARTICLE 8 

CONFIDENTIALITY 

8.1 Article 10 of the License Agreement (Confidentiality) is hereby incorporated into this Supply Agreement by reference. The terms and
provisions of this Supply Agreement (which shall be the Discloser’s Information of both Parties) and all other information and data, including all notes, books, papers, diagrams, documents, reports,
e-mail, memoranda, visual observations, oral communications and all other data or information in whatever form, that one Party or any of its Affiliates or representatives supplies or otherwise makes available
to the other Party or its Affiliates or representatives pursuant to this Supply Agreement shall be deemed Discloser’s Information pursuant to Article 10 of the License Agreement. 

ARTICLE 9 

INDEMNIFICATION AND INSURANCE 

9.1 Indemnification. 

9.1.1 Indemnification by Sutro. Sutro hereby agrees, at its sole cost and expense, to defend, hold harmless and indemnify, to the extent
permitted by Applicable Law, (collectively, “Indemnify”) SutroVax and its Affiliates and their respective agents, directors, officers and employees of such Persons and the respective successors and assigns of any of the foregoing
(the “SutroVax Indemnitees”) from and against any and all liabilities, damages, penalties, fines, costs and expenses (including, reasonable attorneys’ fees and other expenses of litigation) (collectively,
“Liabilities”) resulting from suits, claims, actions and demands, in each case brought by a Third Party (each, a “Third-Party Claim”) against any SutroVax Indemnitee and arising from or occurring as a result of:
[***]. Sutro’s obligation to Indemnify the SutroVax Indemnitees pursuant to this Section 9.1.1 shall not apply to the extent that any such Liabilities are the result of a material breach by SutroVax of its obligations,
representations, warranties or covenants under this Supply Agreement or the License Agreement or any SutroVax Indemnitee’ s negligence or willful misconduct. 

9.1.2 Indemnification by SutroVax. SutroVax hereby agrees to Indemnify Sutro and its agents, directors, officers and employees and the
respective successors and assigns of any of the foregoing (the “Sutro lndemnitees”) from and against any and all Liabilities resulting from Third-Party Claims against any Sutro Indemnitee arising from or occurring as a result of:
[***]. SutroVax’s obligation to Indemnify the Sutro Indemnitees pursuant to this Section 9.1.2 shall not apply to the extent that any such Liabilities are the result of a material breach by Sutro of its obligations,
representations, warranties or covenants under this Supply Agreement or the License Agreement or any Sutro Indemnitee’s negligence or willful misconduct. 

 9.1.3 Procedure. To be eligible to be Indemnified hereunder, the indemnified Person
shall provide the indemnifying Party with prompt written notice of the Third-Party Claim giving rise to the indemnification obligation pursuant to this Section 9.1 and the right to control the defense (with the reasonable
cooperation of the indemnified Person) or settlement any such claim; provided, however, that the indemnifying Party shall not enter into any settlement that admits fault, wrongdoing or damages without the indemnified Person’s written consent,
such consent not to be unreasonably withheld or delayed. The indemnified Person shall have the right to join, but not to control, at its own expense and with counsel of its choice, the defense of any claim or suit that has been assumed by the
indemnifying Party. 
 9.2 Insurance. Each Party shall procure and maintain insurance, including clinical trials and product liability
insurance, adequate to cover its obligations hereunder and consistent with normal business practices of prudent companies similarly situated at all times during which any Product or Vaccine Compositions is being clinically tested in human subjects
or commercially distributed or sold by such Party. It is understood that such insurance shall not be construed to create a limit of either Party’s liability or indemnification obligations under this Article 9, or that the maintenance of such
insurance shall not be construed to relieve either Party of its other obligations under this Supply Agreement. Each Party shall provide the other with written evidence of such insurance upon request. Each Party shall provide the other with written
notice at least [***] days prior to the cancellation, non renewal or material change in such insurance. 
 9.3 LIMITATION OF
LIABILITY. EXCEPT (I) WITH RESPECT TO ANY BREACH OF ARTICLE 8 (CONFIDENTIALITY), (II) FOR THIRD PARTY PENALTIES, COSTS AND EXPENSES AS SET FORTH IN SECTION 2.9, OR (III) FOR [***], TO THE MAXIMUM EXTENT PERMITTED BY LAW,
(A) NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL OR PUNITIVE DAMAGES, WHETHER LIABILITY IS ASSERTED IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, OR ANY OTHER THEORY OR FORM
OF ACTION, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY THEREOF; AND (B) EACH PARTY’S TOTAL LIABILITY TO THE OTHER PARTY UNDER THIS SUPPLY AGREEMENT SHALL NOT EXCEED [***]. SUTRO’S LIABITY TO SUTROVAX FOR THIRD PARTY
PENALTIES, COSTS AND EXPENSES UNDER SECTION 2.9 SHALL NOT EXCEED [***]. 
 ARTICLE 10 

TERM AND TERMINATION 

10.1 Term. The term of this Supply Agreement shall begin on the Effective Date first set forth above and shall remain in effect until
the later of (a) July 31, 2021 or (b) the date that the Parties enter into the Phase 3/Commercial Supply Agreement and Sutro is supplying to SutroVax each Product under the Phase 3/Commercial Supply Agreement (the
“Term”), unless it is terminated earlier in accordance with Section 10.2. 
 10.2
Termination. Notwithstanding anything to the contrary in this Supply Agreement, this Supply Agreement may be terminated: 
 10.2.1 in its
entirety or with respect to one or more Products, on a Product-by-Product basis, by mutual written consent of Sutro and SutroVax; 

 10.2.2 in its entirety by a Party if the other Party materially breaches any of the material
terms, conditions or agreements contained in this Supply Agreement to be kept, observed or performed by the other Party, by giving the Party who committed the breach [***] days’ prior written notice, unless the notified Party shall have cured
the breach within such [***]-day period; and 
 10.2.3 in its entirety or with respect to one or more
Products, on a Product-by-Product basis, by SutroVax upon [***] days’ prior written notice to Sutro for any reason. 

10.3 Effects of Termination. Upon the expiration of the Term or termination of this Supply Agreement, in its entirety or with respect to
one or more Products, this Supply Agreement shall, except as otherwise provided in this Section 10.3 or Section 10.5, be of no further force or effect; provided, however, that (a) in the event
this Supply Agreement is terminated by SutroVax pursuant to Section 10.2.3 and there are outstanding Work Orders or other purchase orders accepted by Sutro that would not be fulfilled as a result of such termination,
SutroVax shall reimburse Sutro for all supplies and materials purchased by Sutro and time incurred by Sutro personnel (to the extent incurred solely for manufacture of Product for SutroVax) for the manufacture, or preparation for the manufacture, of
Products for any Work Orders placed by SutroVax and any other purchase orders accepted by Sutro prior to such expiration or termination, in each case to the extent Sutro cannot otherwise reasonably mitigate such the costs and expenses of such
supplies, materials and time (e.g., by use of resulting supplies, materials and work-in-progress Product for other purposes); provided that to the extent SutroVax pays for any supplies or materials, upon
SutroVax’s request Sutro shall promptly transfer and deliver such supplies and materials to SutroVax; and (b) if this Supply Agreement is terminated with respect to one or more Products, but not all Products, then this Supply Agreement
shall continue in full force and effect with respect to the applicable Product(s) for which it is not terminated. 
 10.4 Nonexclusive
Remedy. Exercise of any right of termination afforded to either Party under this Supply Agreement (i) shall not prejudice any other legal rights or remedies either Party have against the other in respect of any breach of the terms and
conditions of this Supply Agreement, and (ii) shall be without any obligation or liability arising from such termination other than such obligations expressly arising from termination of this Supply Agreement. 

10.5 Survival. Expiration of the Term or termination of this Supply Agreement (for any reason) shall not affect any accrued rights or
liabilities of either Party. Article 4 (Product Testing), Article 5 (Inspection), Article 8 (Confidentiality), Article 9 (Indemnification and Insurance), Article 11 (Disputes), Article 12 (Miscellaneous),
and Sections 2.2 (Transfer of Product), 2.14 (Phase 3/Commercial Supply Agreement), 2.15 (Qualification of Alternate Supplier), 2.17 (Manufacture of Custom Reagents), 3.3 (Recordkeeping), 3.4
(Taxes), 6.2 (Right of Reference; Drug Master Files), 6.3 (Recalls), 6.4 (Retention of Samples), 6.5 Regulatory Authority Inspections and Correspondence), 7.3 (Product Warranties), 7.4 (Disclaimer),
10.3 (Effects of Termination), 10.4 (Nonexclusive Remedy), and 10.5 (Survival) shall survive any expiration of the Term or termination of this Supply Agreement. 

 ARTICLE 11 

DISPUTE RESOLUTION 

11.1 Principal Contacts. Each Party will appoint an individual employed by it to serve as its “Principal Contact” for
purposes of this Supply Agreement. Either Party may from time to time replace its Principal Contact with a different employee, but unless required due to events beyond its control, neither Party will replace its Principal Contact without at least
[***] days prior notice to the other Party. The two Principal Contacts shall communicate with each other regularly during the Term as the Parties may agree or as the Principal Contacts shall mutually determine to be useful. 

11.2 Escalation. The Parties intend that, to the maximum extent practicable, they shall reach decisions hereunder cooperatively through
discussions among the Principal Contacts and by mutual consent of the Parties. In situations in which that does not occur, disputes or differences arising out of or in connection with this Supply Agreement shall initially be referred for review by
the Parties’ respective Senior Managements (as defined below). Such Senior Managements shall discuss the proposed dispute or difference, and shall meet with respect thereto if either of them believes a meeting or meetings are likely to be
useful. If the Senior Managements do not resolve the dispute or difference within [***] days (or such lesser or longer period as they may agree is a useful period for their discussions), then either Party may pursue its other available remedies,
consistent with this Supply Agreement. As used herein, Sutro’s “Senior Management” means its then-current CEO, and SutroVax’s “Senior Management” means its then-current CEO. For clarity, there shall be no
obligation for any Disputed Matter arising out of Section 2.14 or 2.15 to be referred to the Senior Management to review prior to such matters being resolved by arbitration pursuant to Sections 11.3 and 11.4. 

11.3 Arbitration. If the Senior Managements are not able to resolve such dispute referred to them under Section 11.2 within such
[***] day period, then such dispute shall be resolved by final and binding arbitration as follows: The Parties shall select a mutually agreeable arbitrator who has significant relevant experience in the subject matter of the disputed issue and no
affiliation or pre-existing relationship with either Party. If the Parties cannot agree on an arbitrator within [***] days after the end of the [***] day period referred in Section 11.2 (or with respect
to a Disputed Matter described in Section 11.4, after referral by a Party of such Disputed Matter to arbitration), either Party may request the Judicial and Mediation Services (“JAMS”) in San Francisco, CA to appoint an
arbitrator on behalf of the Parties in accordance with the commercial arbitration rules of JAMS, and the proceeding shall be conducted in accordance with JAMS rules. The arbitrator may decide any issue as to whether, or as to the extent to which,
any dispute is subject to the arbitration and other dispute resolution provisions in this Supply Agreement. The arbitrator must base the award on the provisions of this Supply Agreement and must render the award in a writing which must include an
explanation of the reasons for such award. Judgment upon the award rendered by the arbitrator may be entered by any court having jurisdiction thereof. The arbitrator’s fees and expenses shall be shared equally by the Parties, unless the
arbitrator in the award assesses such fees and expenses against one of the Parties or allocates such fees and expenses other than equally between the Parties. Each Party shall bear and pay its own expenses incurred in connection with any dispute
resolution under this Section 11.3. Notwithstanding the foregoing, either Party shall have the right, without waiving any right or remedy available to such Party under this Supply Agreement or otherwise, to seek and obtain from any court of
competent jurisdiction any interim or provisional relief that is necessary or desirable to protect the rights or property of such Party, pending the selection of the arbitrator hereunder or pending the arbitrator’s decision of the dispute
subject to arbitration. 

 11.4 Baseball Arbitration. In the event (a) the Parties do not enter into a
Phase 3/Commercial Supply Agreement as described in Section 2.14 or (b) the Parties do not enter into a Transfer Addendum as described in Section 2.15 (“Disputed Matter”), then upon either Party’s request with
respect to the Disputed Matter in clause (a) or SutroVax’s request with respect to the Disputed Matter in clause (b), such Disputed Matter shall be resolved by binding arbitration conducted pursuant to Section 11.3, except that the
procedures for the conduct of such arbitration shall be as follows: 
 11.4.1 Each Party shall provide the arbitrator and the other Party
with a written report setting forth its position with respect to the substance of such Disputed Matter and a full draft Phase 3/Commercial Supply Agreement or Transfer Addendum, as applicable, and may submit a revised report, position and draft
Phase 3/Commercial Supply Agreement or Transfer Addendum, as applicable, to the arbitrator within [***] days of receiving the other Party’s report and draft Phase 3/Commercial Supply Agreement or Transfer Addendum, as applicable. If so
requested by the arbitrator, each Party shall make oral and/or other written submissions to the arbitrator in accordance with procedures to be established by the arbitrator; provided that other Party shall have the right to be present during any
oral submissions. The arbitrator shall select one of the Party’s draft Phase 3/Commercial Supply Agreement or Transfer Addendum, as applicable, as his or her decision, based on what is most reasonable and equitable to each of the Parties under
the circumstances and reflective of reasonable and customary terms in the biopharmaceutical industry for agreements of this type and most closely reflects the Parties’ intent as expressed in this Supply Agreement and the License Agreement, and
shall not have the authority to render any substantive decision other than to so select the draft Phase 3/Commercial Supply Agreement or Transfer Addendum, as applicable, of Sutro or SutroVax (as initially submitted, or as revised in accordance with
the foregoing, as applicable). For clarity, it is understood that the Parties intend the arbitration under this Section 11.4 to be a “baseball arbitration” type proceeding; and the arbitrator may fashion such detailed procedures as
the arbitrator considers appropriate to implement this intent. Notwithstanding anything to the contrary, in no event shall the Phase 3/Commercial Supply Agreement or Transfer Addendum contain any provision granting to SutroVax or its Affiliates or
Sublicensees any right to obtain or use any Sutro Core Know-How. 
 11.4.2 In any arbitration under
this Section 11.4, the arbitrator and the Parties shall use their best efforts to resolve such Disputed Matter within [***] days after the selection of the arbitrator, or as soon thereafter as is practicable. 

ARTICLE 12 

MISCELLANEOUS 

12.1 Expenses. Except as otherwise expressly provided herein, each Party shall bear its own costs, fees and expenses incurred by such
Party in connection with this Supply Agreement. 
 12.2 Licenses and Permits. Each Party shall, at its sole cost and expense, maintain
in full force and affect all necessary licenses, permits, and other authorizations required by Applicable Law in order to carry out its duties and obligations hereunder. 

 12.3 Force Majeure. No Party shall be liable for a failure or delay in performing any
of its obligations under this Supply Agreement if, but only to the extent that such failure or delay is due to causes beyond the reasonable control of the affected Party, including: (a) acts of God; (b) fire, explosion, or unusually severe
weather; (c) war, invasion, riot, terrorism, or other civil unrest; (d) governmental laws, orders, restrictions, actions, embargo or blockages; (e) national or regional emergency; (f) strikes or industrial disputes at a national
level which directly impact the affected Party’s performance under this Supply Agreement; or (g) other similar cause outside of the reasonable control of such Party (“Force Majeure”); provided that the Party affected shall
promptly notify the other of the Force Majeure condition and shall use reasonable efforts to eliminate, cure or overcome any such causes and resume performance of its obligations as soon as possible. If the performance of any obligation of a Party
under this Supply Agreement is delayed owing to such a Force Majeure for any continuous period of more than [***] days, the other Party shall have the right to terminate this Supply Agreement. 

12.4 Neither Party may assign or transfer this Supply Agreement, including by merger, operation of law, or otherwise, without the other
Party’s prior written consent (which shall not be withheld unreasonably) except each Party may assign this Supply Agreement without the other Party’s consent in the case of assignment or transfer to a Third Party that succeeds to all or
substantially all of the assigning Party’s business and assets relating to the subject matter of this Supply Agreement, whether by sale, merger, operation of law or otherwise. Any attempted assignment by a Party in violation of this Section
without the written consent of the other Party will be null and void. Except as above limited, this Supply Agreement is binding upon and will inure to the benefit of each of the Parties, its successors and assigns. Without limiting the foregoing, in
the event that a Party is acquired, the acquiring Party shall agree in writing to abide by the terms of this Supply Agreement. Sutro agrees that if it assigns the License Agreement to any successor as allowed under section 15.1 of the License
Agreement, it will also assign to such successor this Supply Agreement in accordance with this Section 12.4. 
 12.5 This Supply
Agreement incorporates the Exhibits referenced herein. This Supply Agreement, together with the License Agreement, constitutes the entire agreement and supersedes all prior agreements and understandings, both written and oral, between the Parties
hereto with respect to its subject matter. To the extent of any conflict between this Agreement and the License Agreement, the License Agreement shall govern and control. 

12.6 All notices, requests or other communication provided for or permitted hereunder shall be given in writing and shall be hand
delivered or sent by confirmed facsimile, reputable courier or by registered or certified mail, postage prepaid, return receipt requested, to the address set forth below, or to such other address of which either Party may inform the other in
writing. Notices will be deemed delivered on the earliest of transmission by facsimile, actual receipt or [***] days after mailing as described herein. 

If to Sutro:    Sutro Biopharma, Inc. 

310 Utah Ave., Suite 150 
 South
San Francisco, CA 94080 
 Attention: Chief Executive Officer 

 If to SutroVax:    SutroVax, Inc. 

 353 Hatch Dr. 

 Foster City, CA 94404 

 Attention: Chief Executive Officer 

12.7 This Supply Agreement may be amended, modified or waived only in a writing signed by the Party or Parties to be bound thereby. 

12.8 If any provision of this Supply Agreement shall be held invalid, illegal or unenforceable, such provision shall be enforced to the
maximum extent permitted by law and the Parties’ fundamental intentions hereunder, and the remaining provisions shall not be affected or impaired. 

12.9 Nothing herein contained shall constitute this a joint venture agreement and nothing herein shall constitute any Party as a
partner, principal or agent of any other, this being an agreement between independent contracting entities. Except as expressly set forth herein, no Party shall have the authority to bind any other in any respect whatsoever to Third Parties. Except
as provided herein, nothing contained in this Supply Agreement shall be construed as conferring any right on any Party to use any name, trade name, trademark or other designation of any other Party hereto, unless the express, written permission of
such other Party has been obtained. 
 12.10 This Supply Agreement has been submitted to the scrutiny of, and has been negotiated by,
both Parties and their counsel, and shall be given a fair and reasonable interpretation in accordance with its terms, without consideration or weight being given to any such term’s having been drafted by any Party or its counsel. 

12.11 This Supply Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of California,
without regard to any conflict of laws rules to the contrary. 
 12.12 Each Party acknowledges that the other Party may likely suffer
irreparable harm from such Party’s breach or threatened breach of this Agreement and the other Party, in such cases, would therefore be entitled, without waiving any other right or remedy available to, to injunctive relief (including specific
performance) without the requirement to post a bond, provided the waiver by such Party of the other Party’s requirement to post a bond shall expire on the Change of Control of the other Party, and each party agrees that the arbitrator selected
under Section 11.3 shall have the power to grant such injunctive relief (or order specific performance). The Parties shall comply with any such injunctive relief (including specific performance) ordered by the arbitrator and agree that such
order may, to the extent not precluded by applicable law, be enforceable as a final award in any court of competent jurisdiction. 
 12.13
This Supply Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile and other electronically scanned signatures
shall have the same effect as their originals. 
 [The remainder of this page is left intentionally blank] 

 IN WITNESS WHEREOF, the Parties have caused this Supply Agreement to be executed by
their respective duly authorized officers as of the Effective Date, each copy of which will for all purposes be deemed to be an original. 
  

									
	SUTRO BIOPHARMA, INC.	  	        	  	SUTROVAX, INC.
					
	By:	  	 /s/ William J. Newell
	  	        	  	By:	  	 /s/ Grant E. Pickering

	Name:	  	William J. Newell	  	        	  	Name:	  	Grant E. Pickering
	Title:	  	CEO	  	        	  	Title:	  	President & CEO

 SCHEDULE 1 

PRODUCTS AND PRICE 
 [***] 

 SCHEDULE2 

SPECIFICATIONS 
 {6 pages omitted}

 [***] 

 SCHEDULE3 

INITIAL ORDER 
 [***] 

 SCHEDULE 2.15.1 

REPRESENTATIVE CMOS 
 [***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}]]